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ABSTRACT 22 
Invasive yeast infections (IYI) represent a serious nosocomial problem. This is 23 
the first Portuguese multicenter prospective, observational and descriptive study that 24 
provides insights on species distribution and susceptibility profile of yeast isolates from 25 
fungemia episodes. All Portuguese hospitals were invited to integrate this study during 26 
2012 (a twelve-month period). Ten district hospitals across mainland Portugal 27 
contributed by collecting yeast isolates from blood cultures and answering 28 
questionnaires concerning patients’ data. The susceptibility profile of each isolate, 29 
considering eight of the most used antifungals, was determined. Two hundred and 30 
forty yeast isolates were recovered and identified. Incidence of fungemia was 31 
0.88/1000 admissions. Fifteen different species were found, with Candida albicans as 32 
the most prevalent; however, 60% of fungemias were caused by non-albicans species. 33 
Most isolates were recovered from patients admitted at surgical wards or Intensive 34 
Care Units with 57% being males and 32% aged 41 to 60 years old. About 13% of yeast 35 
isolates were resistant to fluconazole, 18% to posaconazole and 16% to voriconazole. 36 
Regarding echinocandins, the highest percentage of resistance was to caspofungin 37 
(17%). Rare cases of strains displaying high MIC values to amphotericin B were also 38 
obtained (n=3). Death within 30 days associated with IYI occurred in 25% of the cases 39 
with more than half of C. glabrata infections being fatal. Studies addressing species 40 
distribution and susceptibility profile are extremely valuable as they provide important 41 
clues about worldwide IYI tendencies and may help improving empirical treatment 42 
guidelines. 43 
 44 
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INTRODUCTION  45 
Increased incidence of invasive yeast infections (IYI) represents a clinical 46 
problem and its impact has significantly risen during the last twenty years (1). 47 
Fungemia is an important cause of morbidity and mortality, being related to longer 48 
hospital stays and very high economic costs. Candida albicans still remains as the 49 
leading cause of fungemia worldwide (2). Candida parapsilosis, Candida glabrata and 50 
Candida tropicalis occupy the following places, varying according to the region. Due to 51 
the medical relevance of IYI and its very strong association with an unfavorable 52 
outcome, epidemiological surveillance studies are urgently needed in order to evaluate 53 
species’ geographic distribution and changes in susceptibility profiles. In addition, 54 
there is a limited number of therapeutic options, with the main class of drugs (azoles) 55 
controversially used for prophylaxis, possibly leading to decreased susceptibility and 56 
the selection of non-albicans species. In recent years we have witnessed several 57 
worldwide epidemiological and clinical changes regarding IYI (3-5). The aim of this 58 
study was to provide an overview about IYIs in Portugal and to evaluate the 59 
susceptibility profile of yeasts isolated from blood cultures. 60 
 61 
MATERIALS AND METHODS 62 
Study design Ten hospitals from northern (four), central (two) and southern 63 
(four) regions of Portugal accepted to participate in this study, providing isolates 64 
collected from patients with fungemia from September 2011 to September 2012. Two 65 
hospitals had more than 1000 beds, 3 had between 600 and 1000 beds and 5 had less 66 
than 600 beds. All participating hospitals were asked to collect and send the strains to 67 
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the Microbiology Department of the Faculty of Medicine of the University of Porto, 68 
where the study was conducted. In addition, a questionnaire regarding patient’s 69 
clinical and demographic data was also sent.  70 
Definitions An episode of fungemia was defined as the first isolation from a 71 
blood culture of a yeast strain from a patient with related signs and symptoms. 72 
Nosocomial fungemia was defined whenever the yeast isolate was obtained more than 73 
48h after hospital admission. Ages were grouped into five categories: less than 20 74 
years, 20-40 years, 41-60 years, 61-70 years and more than 70 years old. For each 75 
individual patient, the outcome of the fungemia episode was evaluated at 30 days 76 
after the first yeast isolation. Death associated with fungemia was defined as death 77 
within 30 days after recovery of the first yeast isolate, without any other concomitant 78 
cause of death, like intracerebral or gastrointestinal bleeding or pulmonary embolism.  79 
Identification and in vitro antifungal susceptibility testing of yeast isolates 80 
Yeasts were identified using Vitek 2 YST card from bioMérieux (Paris, France). The 81 
characterization of Candida glabrata sensu stricto, Candida bracarensis and Candida 82 
nivariensis was confirmed as previously described by Romeo et al (6). Candida 83 
parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis isolates were 84 
identified as previously described by Tavanti et al (7). Furthermore, the identities of 85 
these species were confirmed by DNA amplification and further sequencing of ITS1 and 86 
ITS4 regions of rRNA genes. Minimal inhibitory concentrations (MIC) were determined 87 
by broth microdilution, following the CLSI guidelines (8). Antifungal powders were 88 
obtained from the manufacturers - fluconazole (FLC), voriconazole (VRC) and 89 
anidulafungin (AND) [from Pfizer, Groton, C.T., USA], posaconazole (POS) [Schering-90 
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Plough Research Institute, Kenilworth, N.J., USA], caspofungin (CAS) [from Merck, 91 
Rahway, N.J., USA], micafungin (MCF) [from Astelas Pharma, UK], flucytosine (5FC) 92 
[Roche Laboratory Inc., Nutley, N.J., USA] and deoxycholate amphotericin B (AMB) 93 
[Bristol-Myers Squibb, N.Y., USA]. FLC, CAS and MCF were dissolved in water and the 94 
other drugs in DMSO. The new species-specific breakpoints for FLC, VRC and 95 
echinocandins were applied (8, 9). Isolates of C. albicans, C. tropicalis and C. 96 
parapsilosis for which FLC MICs were ≤2mg/L were categorized as susceptible and 97 
resistant at MICs >4 mg/L. C. glabrata was considered FLC susceptible-dose dependent 98 
(S-DD) at MICs ≤32 mg/L and resistant at MICs >32 mg/L. C. albicans, C. tropicalis, and 99 
C. parapsilosis were classified as susceptible to VRC at MICs ≤0.125 mg/L, and as 100 
resistant at ≥1 mg/L, and for C. krusei, susceptible when MICs ≤0.5 mg/L and resistant 101 
if >1 mg/L. Isolates of C. albicans, C. tropicalis, and C. krusei, for which AND, CAS and 102 
MCF MICs were ≤0.25 mg/L, were classified as susceptible and >0.5 mg/L as resistant. 103 
C. glabrata was categorized as susceptible when AND or CAS MICs were ≤0.12 mg/L 104 
and as resistant when >0.25 mg/L, while for MCF they were ≤0.06 mg/L (susceptible) 105 
and >0.12 mg/L (resistant). C. parapsilosis and Candida guilliermondii were classified as 106 
susceptible or resistant when MICs of the three echinocandins were ≤2 mg/L and >4 107 
mg/L, respectively. For POS and 5FC the epidemiological cut-off values were applied to 108 
separate the wild type from non-wild type isolates: 0.06 mg/L for C. albicans, 0.12 109 
mg/L for C. tropicalis, 0.25 mg/L for Candida lusitaniae and C. parapsilosis, 0.5 mg/L for 110 
C. krusei and 2 mg/L for C. glabrata for POS; and for 5FC it was 0.5 mg/L for C. albicans, 111 
C. tropicalis, C. glabrata and C. parapsilosis and 32 mg/L for C. krusei (9-11). MICs were 112 
registered after 24 and 48 hours for Candida species and after 48 and 72 hours for 113 
Cryptococcus neoformans. Since breakpoints for AMB have not yet been established, 114 
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yeasts inhibited by ≤1 mg/L were considered to be susceptible according to 115 
suggestions by Pfaller et al (11). The quality control (QC) strains C. parapsilosis ATCC 116 
22019 and C. krusei ATCC 6258 were included in all assays (8). 117 
Statistical analysis A descriptive revision of the collected data was performed 118 
using the statistic program SPSS v21.0 (SPSS Software, Chicago, USA). The Chi-square 119 
test was used to compare proportions and analyze differences in the species 120 
distribution and in antifungal susceptibility profiles. 121 
 122 
RESULTS 123 
Patient’s data A total of 240 fungemia episodes were reported in the current 124 
survey (corresponding to 240 different patients) and included in the study. The mean 125 
incidence of fungemia was 0.88 per 1000 admissions, ranging from 0.15 to 2.4. The 126 
mean incidence of nosocomial fungemia was 0.74 per 1000 admissions, ranging from 127 
0.14 to 2.1, and corresponding to approximately 86% of all episodes of fungemia. Fifty-128 
seven per cent of patients with fungemia were males and the most affected group was 129 
the one aged 41-60 years old (32%) closely followed by the group of patients over 70, 130 
together accounting for 62% of cases (Table1). Most patients enrolled in this study 131 
were admitted at ICU (39%) and surgical wards (30%). The crude mortality rate 132 
associated with fungemia was 25%. The deadliest species was C. glabrata, with more 133 
than 50% of patients dying within 30 days of fungemia detection. The other main 134 
Candida species did not differ much from the general value. (Table 1) 135 
 136 
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Species distribution and identification Fifteen different yeast species were 137 
identified, with the five most prevalent being C. albicans (40.4%), C. parapsilosis 138 
(22.9%), C. glabrata (13.3%), C. tropicalis (6.3%) and C. krusei (5%). C. neoformans was 139 
responsible for eight (3.3%) episodes of fungemia followed by C. lusitaniae (2.5%), 140 
Candida guilliermondii (1.7%), Candida dubliniensis (1.3%) and Candida famata (1.3%). 141 
Single cases due to Candida sake, Candida inconspicua, Candida haemulloni, Candida 142 
kefyr and Trichosporon mucoides were also found, as a whole accounting for 1.7% of 143 
all cases. Regarding the molecular identification of the cryptic species, from 55 isolates 144 
of C. parapsilosis sensu lato, 49 corresponded to C. parapsilosis sensu stricto, 4 to C. 145 
orthopsilosis (3 isolated from Medicine Department and 1 from UCI; 1 belonging to a 146 
52 years old and the other 3 to patients over 70 years old) and 2 to C. metapsilosis 147 
(both from the Medicine Department; one from a 17 year old patient and the other 148 
from a 32 year-old patient). The 32 isolates primarily identified as belonging to the C. 149 
glabrata group corresponded to C. glabrata sensu stricto. There were no significant 150 
differences in the species distribution by gender or age (for a p value of 0.05).  151 
Species susceptibility profiles Table 2 summarizes susceptibility testing results; 152 
endpoints shown were obtained after 24h of incubation and they differ no more than a 153 
single dilution from those obtained after 48h. Global antifungal resistance rates were 154 
calculated (considering the five main species, except for FLC, where C. krusei were 155 
excluded on the basis of intrinsic resistance; for the echinocandins the four isolates of 156 
C. guilliermondii were taken into account; for POS, epidemiological cutoff values were 157 
used). Among the group of azoles, the highest resistance rate was observed for POS 158 
(18.5%), followed by VRC (15.6%) and FLC (13.1%). Concerning the echinocandins, CAS 159 
was the drug with the most resistances (17.2% of isolates), surpassing AND (14.0%) 160 
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and MCF (11.6%). Resistance to 5FC was rare. In the matter of simultaneous resistance 161 
to antifungals of different classes (excluding strains with intrinsic resistances such as C. 162 
krusei for FLC and C. neoformans to echinocandins), we detected one isolate of T. 163 
mucoides (resistant to FLC, AND, CAS and MCF), one of C. krusei (resistant to AMB and 164 
CAS) and one of C. parapsilosis (resistant to FLC and CAS). Resistance to drugs within 165 
the same class was more frequent, with 8 strains of C. albicans and 1 of C. tropicalis 166 
displaying resistance to the three azoles and 6 strains of C. parapsilosis resistant to the 167 
three echinocandins (MIC ≥8mg/L). Regarding the in vitro activity of AMB, with the 168 
exception of three isolates (one each of C. glabrata, C. krusei and C. kefyr) which 169 
corresponded to a high MIC value (2 mg/L), all the other strains were susceptible with 170 
very low MIC values, ranging from 0.03 to 0.125 mg/L. Susceptibility testing results 171 
revealed C. parapsilosis as the most resistant species to echinocandins, with only 20% 172 
of the isolates susceptible to the 3 antifungals (resistance rate of 31% to MCF, 53% to 173 
AND and 51% to CAS). On the other hand, C. albicans displayed high susceptibility to 174 
these drugs but considerable resistance to azoles (18.6% to FLC, 18.6% to VRC and 175 
16.5% to POS). Almost one third of C. glabrata exhibited a high MIC of VRC, with lower 176 
values to other azoles (6.25% for POS and FLC) and echinocandins (18.75% for MCF, 177 
9.4% to CAS and 0% to AND). All C. tropicalis isolates were susceptible to 178 
echinocandins, but there were resistances to azole antifungals (60% to POS, 33% to 179 
VRC and 20% to FLC). C. krusei was susceptible to the azoles (apart from the expected 180 
resistance to FLC), AND and MCF. High MIC values to CAS were found in 5 isolates 181 
(41.6%). All the participating hospitals had Intensive Care Units (ICU) and Pediatric 182 
Departments and although very distinct geographic areas were covered by these 183 
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hospitals, no significant differences in species distribution and the antifungal 184 
susceptibility profile were found (for p=0.05). 185 
DISCUSSION  186 
Our study reports an incidence of fungemia of 0.88/1000 admissions (ranging 187 
from 0.15 to 2.4), figures comparable to recent data from other European countries 188 
(12, 13) albeit somewhat lower than in Brazil (14). A previous study in Portugal, based 189 
on a single university hospital, uncovered a similar, though slightly higher, incidence of 190 
2.7/1000 admissions (15). Healthcare-associated fungemia remains the vast majority, 191 
representing more than 80% in most works (16, 17). Thus, it is not unsurprising that 192 
most of the isolates were recovered from ICU, surgery and internal medicine 193 
departments, given that most patients admitted to these wards are in critical health 194 
conditions and are submitted to invasive procedures, aggressive antibiotic and 195 
immunosuppressive drug regimens and placement of indwelling devices (central and 196 
peripheral venous catheters, urinary catheters and invasive ventilation procedures), all 197 
previously associated with increased rates of fungal infections (18-21). We report a 198 
crude 30-day mortality rate of 25%, with more than half (53%) of C. glabrata 199 
fungemias being lethal. Costa-de-Oliveira et al. reported, five years ago, even higher 200 
values, with a 78% mortality rate for C. glabrata fungemia and 46%, 30% and 53% for 201 
C. albicans, C. parapsilosis and C. tropicalis, respectively (15). The reasons behind this 202 
decrease can only be speculated. In other European studies crude mortality rates due 203 
to fungemia ranged from around 30% (12, 16) to 40%(17, 22), but C. glabrata did not 204 
carry a heavier death burden. C. albicans appears as the leading causative agent of 205 
fungemia in our study (40%) and in other European studies, accounting for an even 206 
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higher proportion of cases (12, 16, 22-24). However, the second position is not 207 
occupied by C. parapsilosis in most European countries; instead, C. glabrata appears 208 
repeatedly as the most common non-albicans species isolated from blood cultures (2), 209 
reaching almost a third of all Candida strains in some studies (17, 23). In fact, some 210 
authors place C. parapsilosis in the fourth (16) or even fifth position (23), behind C. 211 
tropicalis and C. krusei. The causes of this difference in incidences are unknown to us. 212 
Curiously, our data parallels those of Spanish and Brazilian works, where C. parapsilosis 213 
is responsible for 27 and 37% of cases of fungemia (13, 25). Taking into account the 214 
recent separation of the cryptic species in the C. parapsilosis and C. glabrata 215 
complexes into species in their own right, we strived to identify these in our studies. C. 216 
orthopsilosis and C. metapsilosis represented 7.3 and 3.6%, respectively, of the C. 217 
parapsilosis sensu lato isolates, while C. nivariensis and C. bracarensis were not 218 
identified, coinciding with results in other Mediterranean countries (13, 26, 27) and 219 
Brazil (25). In our work we applied the new CLSI M27-S4 breakpoints for antifungal 220 
susceptibilities (9), which may have altered the final resistance values for the five main 221 
species. Comparison with other studies is hindered by the fact that most prior works 222 
do not use these breakpoints and a large part of those that do does not present the 223 
susceptibility results as MIC distribution in the range of tested antifungal 224 
concentrations. Our work does show relatively high resistance rates to azoles and 225 
echinocandins, compared to other countries (28). However, it is important to highlight 226 
the small size of our sample and point out that more isolates (either through greater 227 
participation or by extending the period of the study) would strengthen our results. 228 
Mortality due to fungemia remains at unacceptably high values. Studies like the one 229 
we present (the first multicenter study carried out in Portugal) are of utmost 230 
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importance, for they provide invaluable data on the species distribution and antifungal 231 
susceptibility, and can guide clinicians in the treatment of these infections. 232 
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Table 1 - Distribution of the isolated yeast strains
 No. of isolates (%) 
 C. albicans C. parapsilosis C. glabrata C. tropicalis C. krusei Other species Overall 
Gender 
Male 59 (61) 26 (47) 21 (66) 11 (73) 4 (33) 16 (55) 137 (57) 
Female 38 (39) 29 (53) 11 (34) 4 (27) 8 (67) 13 (45) 103 (43)
Total 97 (40) 55 (23) 32 (13) 15 (6) 12 (5) 29 (12) 240 (100) 
Age group (years) 
<20 8 (8) 13(23) 1(3) - - 12 (42) 34 (14) 
20-40 10 (10) 4(7) 3(9) 2(13) 2(17) 6 (21) 27 (11) 
41-60 35 (35) 13(24) 9(29) 7(47) 6(50) 7 (24) 77 (32) 
61-70 15 (16) 7(13) 3(9) 3(20) 1(8) 2 (7) 31 (13) 
>70 29 (30) 18(32) 16(50) 3(20) 3(25) 2 (7) 71 (30) 
Hospital Department 
ICU 42(43) 21(38) 12 (38) 4(27) 5(42) 10 (35) 94(39)
Surgery 22 (23) 18(33) 8(25) 8(53) 3(25) 11 (38) 70(30)
Medicine 28 (29) 13(24) 11(34) 3(20) 4(33) 6 (21) 65(27) 
Pediatrics 5 (5) 3 (6) 1(3) - - 2 (7) 11 (5) 
Outcome 
Death 30 days 23 (24) 12 (22) 17 (53) 3 (20) - 4 (14) 59 (25) 
 
 
 
 
 
 380 
 381 
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Table 2 – Distribution of MIC values according to the species 382 
Species (no.isolates) Drug R breakpoint or ECV 
No. of isolates with MIC (mg/L) 
No (%) of Resistance 0,015 0,03 0,06 0,125 0,25 0,5 1 2 4 8 16 32 64 128 
C. albicans (97) 
AND >0.5 91 2 3      1  - - - - 1 (1) 
CAS >0.5  86 1 1 5 3 1    - - - - 1 (1) 
MCF >0.5 82 1 3 2 4 3  1  1 - - - - 2 (2.1) 
FLC >4 - - - 8 31 24 15 1  17  1  18 (18.6) 
VOR >0.5 - 58 7 11 1 2  2 12 4 - - - 18 (18.6) 
POS >0.06* - 81  1      4 11 - - - 16 (16.5) 
AMB >1 11 21 54 1 2 4 4    - - - - 0 
5FC >0.5* - - - 61 18 10 5 2    1 - 8 (8.2) 
C. parapsilosis (55) 
AND >4    1 1 4 1 6 13 19 10 - - - 29 (52.7) 
CAS >4  1 2 1 1 3 12  7 20 8 - - - 28 (50.9) 
MCF >4  4  8 2 4 9 3 8 6 8 3 - - 17 (30.9) 
FLC >4 - - -  16 27 4 2 3 1 2   3 (5.5) 
VOR >0.5  17  23 8 7     - - - 0 
POS >0.25*   31 12  9 2 1   - - - 12 (21.8) 
AMB >1  42 8 4 1      - - - 0 
5FC >0.5* - - - 49 3 2 1      1 (1.8) 
C. glabrata (32) 
AND >0.25  19 8 3 2      - - - - 0 
CAS >0.25  13 9 3 4 2   1  - - - - 3 (9.4) 
MCF >0.12  21  5  2 3  1  - - - - 6 (18.75) 
FLC >32 - - -   2 1 8 7 12  2  2 (6.25) 
VOR >0.5*   8 3 9 2 6  3 1 - - - 10 (31.25) 
POS >2*   4 5 5 3 9 4  2 - - - 2 (6.25) 
AMB >1  4 9 7 6 3 2 1     1 (3.1) 
5FC >0.5* - - - 22 2 5 3      3 (9.4) 
C.tropicalis (15) 
AND >0.5  7 3 4 1      - - - - 0 
CAS >0.5  6 3 2 4      - - - - 0 
MCF >0.5  3  5 3 4     - - - - 0 
FLC >4 - - - 5 3 3   1 2  1  3 (20) 
VOR >0.5  1 3 1 5  3  2  - - - 5 (33.3) 
POS >0.12*  2 1 3 4 1 1  2 1 - - - 9 (60) 
20 
 
AMB >1  12 3          0 
5FC >0.5*    6 4 3   1 1   2 (13.3) 
C. krusei (12) 
 
AND >0.5  8  2 2      - - - - 0 
CAS >0.5    3 2 2 3 1 1  - - - - 5 (41.6) 
MCF >0.5    3 6 3     - - - - 0 
FLC >64*           2 7 3  - 
VOR >1  6 5 1       - - - 0 
POS >0.5*  3 1 1 7      - - - 0 
AMB >1  9 1  1   1     1 (8.3) 
5FC >32*         2 3 6 1  0 
 AND >2 5 4 1 12 1 1 3 1 1      1 
 CAS >2 6 1 4 3 1 10 1 2 1      1 
 MCF >2 4 2 5 2 3 2 4 4 2 1     3 
Other spp. (29) FLC >64 
 5 1 4 3 6 5  1  
3 
 
1 
 1 
 VOR >4  15 2 3 6 1 2        0 
 POS >4  17 5 3 2 1   1   -   0 
 AMB >1  4 2 7 7 7 1 1       1 
5FC >32  5 8 5 6 2 2   1 1 
Overall (240) 
AND NA 96 40 15 22 7 5 4 7 15 19 10     
CAS NA 6 107 19 13 17 20 17 3 10 20 8     
MCF NA 86 31 8 25 18 18 16 8 11 8 8 3    
FLC NA  5 1 17 53 62 25 11 12 32 7 7 8   
VOR NA  97 25 42 29 12 11 2 17 5      
POS NA  103 42 25 18 14 12 5 3 7 11     
AMB NA 11 92 77 19 17 14 7 3        
5FC NA   5 146 32 26 11 4 3 4 6 2 1   
 383 
*ECV value 
NA = not applicable; Resistant strains are boldface 
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dissemination of new knowledge concerning the laboratory
diagnosis of human and animal infections. In addition, JCM is
an appropriate forum for the publication of information re-
lated to the role of the laboratory in both the management of
infectious diseases and the elucidation of the epidemiology of
infections. Manuscripts which present the results of original
scientific investigations are encouraged. The three principal
attributes that we require of papers published in JCM are time-
liness, relevance to the practice of clinical microbiology, and
quality science. Manuscripts that present information that is
largely only of relevance to a restricted geographic area are
discouraged.
JCM welcomes submission of manuscripts that present the
results of investigations pertaining to new technologies in clin-
ical microbiology when they address new applications, sub-
stantially extend our understanding of the role of the technol-
ogy in the clinical microbiology laboratory, or provide clinical
or laboratory outcome data.
JCM will consider manuscripts which describe truly novel
molecular methods for use in the diagnosis or elucidation of
infection. However, we discourage submission of manuscripts
predicated on the application of previously well-described
methods (e.g., RT-PCR, RAPD analysis, PFGE, and real-time
PCR, etc.), even though the application may be new. Papers
employing established molecular methods will be considered
only when the application is examined in comparison to some
other existing diagnostic method(s). Such comparative studies
should include information regarding assay sensitivity, speci-
ficity, and diagnostic accuracy.
Studies with matrix-assisted laser desorption ionization–
time of flight mass spectrometry (MALDI-TOF MS) as a pri-
mary focus must offer something that is truly novel in order to
merit consideration for publication in JCM, e.g., application of
MALDI-TOFMS to previously unstudied organisms or organ-
ism groups, applications that extend beyond organism identi-
fication, clinical outcome studies, comparisons of different
MALDI-TOF instruments, broad comparisons with conven-
tional methods, or descriptions of modifications of existing
MALDI-TOFMSmethods. JCMwill not considermanuscripts
that describe routine applications of MALDI-TOF MS.
Papers submitted to JCMwithwhole-genome sequencing or
the microbiome as a focus will be considered only when the
studies performed are scientifically sound, the observations
timely and novel, and the information presented of relevance
to the practice of clinical microbiology. Similarly, papers that
convey the results of meta-analysis studies will be considered
when the data presented are extensive and when the observa-
tionsmade in the study are broadly applicable to the practice of
clinical microbiology.
Case Reports will be considered if they are novel, add to
existing knowledge, and are consistent with the primary objec-
tives of the Journal as outlined above. (See “Case Reports” in
the Organization and Format section and the “Case Report”
paragraph under “Full-Length Papers” for descriptions of the
two different types of Case Reports published.)
To ensure the completeness of investigations in which the
performance of various diagnostic assays or methods is pre-
sented, authors are encouraged to refer to the Standards for the
Reporting of Diagnostic Accuracy (STARD) for guidance. The
entire set of guidelines, including checklists, may be found at
http://stard-statement.org/.
ASM publishes a number of different journals covering var-
ious aspects of the field of microbiology. Each journal has a
prescribed scope whichmust be considered in determining the
most appropriate journal for each manuscript.
(i) With respect to antimicrobial agents, JCM will consider
clinically relevant manuscripts (a) that pertain to in vitro sus-
ceptibility test methods; (b) that are concerned with quality
control procedures related to antimicrobial susceptibility tests;
(c) that deal with investigations of test methods aimed at mea-
suring levels of antimicrobial agents in clinical specimens; or
(d) that describe the use of antimicrobial agents as tools in the
isolation, identification, or epidemiologic assessment of mi-
croorganisms associated with disease. Manuscripts pertaining
to other aspects of antimicrobial agents, such as their basic
mechanisms of action, the elucidation of resistance determi-
nants, pharmacokinetics and pharmacodynamics, and the de-
velopment of new agents, will be considered for publication in
Antimicrobial Agents and Chemotherapy.
(ii) Manuscripts that present the results of investigations
with a primary focus on the basic mechanisms of pathogenesis
of microorganisms or the pathophysiology of infections
should be directed to Infection and Immunity (for bacteria,
parasites, and fungi) or the Journal of Virology (for viruses).
(iii) Reports of clinical microbiology investigations or stud-
ies of the hospital population and the environment as they
relate to nosocomial infections should be submitted to JCM.
Manuscripts dealing with ecology or environmental studies or
with the application of microorganisms to agricultural or in-
dustrial processes are more appropriate for Applied and Envi-
ronmental Microbiology.
(iv) Papers involving immunologic assays for use in the di-
agnosis or elucidation of infection, vaccines, or the assessment
and laboratory diagnosis of immunologic diseases (e.g., auto-
immune diseases and primary immunodeficiencies) should be
submitted toClinical and Vaccine Immunology (formerlyClin-
ical and Diagnostic Laboratory Immunology).
Questions about these guidelines may be directed to the ed-
itor in chief of the journal being considered.
If transfer to another ASM journal is recommended by an
editor, the corresponding author will be contacted.
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Note that a manuscript rejected by one ASM journal on
scientific grounds or on the basis of its general suitability for
publication is considered rejected by all other ASM journals.
EDITORIAL POLICY
Use of Microbiological Information
TheCouncil Policy Committee (CPC) of the American Society
for Microbiology affirms the long-standing position of the So-
ciety that microbiologists will work for the proper and benefi-
cent application of science and will call to the attention of the
public or the appropriate authorities misuses of microbiology
or of information derived from microbiology. ASM members
are obligated to discourage any use ofmicrobiology contrary to
the welfare of humankind, including the use of microbes as
biological weapons. Bioterrorism violates the fundamental
principles expressed in the Code of Ethics of the Society and is
abhorrent to ASM and its members.
ASM recognizes that there are valid concerns regarding the
publication of information in scientific journals that could be
put to inappropriate use as described in the CPC resolution
mentioned above. Members of the ASM Journals Board will
evaluate the rare manuscript that might raise such issues dur-
ing the review process. However, as indicated elsewhere in
these Instructions, research articles must contain sufficient de-
tail, and material/information must be made available, to per-
mit the work to be repeated by others. Supply of materials
should be in accordance with laws and regulations governing
the shipment, transfer, possession, and use of biological mate-
rials andmust be for legitimate, bona fide research needs. Links
to, and information regarding, these laws and regulations can
be found at http://www.asm.org/ under the Public Policy tab.
We ask that authors pay particular attention to the NSAR Se-
lect Agents and Toxins list on the CDC website http://www
.selectagents.gov/index.html and the NSABB criteria for iden-
tifying dual use research of concern in the report “Proposed
Framework for the Oversight of Dual Use Life Sciences Re-
search: Strategies for Minimizing the Potential Misuse of Re-
search Information” on the Office of Biotechnology Activities
website http://oba.od.nih.gov/biosecurity/pdf/Framework%
20for%20transmittal%200807_Sept07.pdf (p. 17–22).
Ethical Guidelines
ASM requirements for submitted manuscripts are consistent
with theUniformRequirements forManuscripts Submitted to
Biomedical Journals, as last updated by the International
Committee of Medical Journal Editors in April 2010 (http:
//www.icmje.org/).
Authors are expected to adhere to the highest ethical stan-
dards. The following sections of these Instructions include de-
tailed information about ASM’s ethical standards. Failure to
comply with the policies described in these Instructions may
result in a letter of reprimand, a suspension of publishing priv-
ileges in ASM journals, and/or notification of the authors’ in-
stitutions. Authors employed by companies whose policies do
not permit them to comply with ASM policies may be sanc-
tioned as individuals and/or ASMmay refuse to considerman-
uscripts having authors from such companies. The ASM Jour-
nals Board wishes to clarify the following in particular.
Plagiarism. Misappropriating another person’s intellec-
tual property constitutes plagiarism. This includes copying
sentences or paragraphs verbatim (or almost verbatim)
from someone else’s work, even if the original work is cited
in the references. The NIH ORI publication “Avoiding Pla-
giarism, Self-Plagiarism, and Other Questionable Writing
Practices: a Guide to Ethical Writing” (http://ori.dhhs.gov
/avoiding-plagiarism-self-plagiarism-and-other-questionable
-writing-practices-guide-ethical-writing) can help authors
identify questionable writing practices.
Plagiarism is not limited to the text; it can involve any part of
themanuscript, including figures and tables, in whichmaterial
is copied from another publication without permission and
attribution. An authormay not reuse his or her own previously
published work without attribution; this is considered self-
plagiarism.
Primary publication. Manuscripts submitted to the jour-
nalmust represent reports of original research, and the original
data must be available for review by the editor if necessary.
By submission of a manuscript to the journal, the authors
guarantee that they have the authority to publish the work
and that the manuscript, or one with substantially the same
content, was not published previously, is not being consid-
ered or published elsewhere, and was not rejected on scien-
tific grounds by another ASM journal. It is incumbent upon
the author to acknowledge any prior publication, including
his/her own articles, of the data contained in a manuscript
submitted to an ASM journal. A copy of the relevant work
should be submitted with the paper as supplemental material
for information only. Whether the material constitutes the
substance of a paper and therefore renders the manuscript un-
acceptable for publication is an editorial decision.
In brief, a paper is not acceptable for submission to an ASM
journal if it, or its substance, has been made publicly available
in:
• A serial, periodical, or book
• A conference report or symposium proceedings
• A technical bulletin or company white paper
• A public website
• Any other retrievable source
The following do not preclude submission to, or publication
by, anASM journal, as long as the posted data donot constitute
the substance of a submission:
• Posting of a method/protocol on a public website
• Posting of a limited amount of original data on a per-
sonal/university/corporate website or websites of small
collaborative groups working on a problem
• Deposit of unpublished sequence data in a public da-
tabase
• Preliminary disclosures of research findings asmeeting
posters, webcast as meeting presentations, or pub-
lished in abstract form as adjuncts to a meeting, e.g.,
part of a program
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• Posting of theses and dissertations on a personal/uni-
versity-hosted website
Availability of materials. By publishing in the journal, the
authors agree that, subject to requirements or limitations im-
posed by laws or governmental regulations of the United
States, any DNAs, viruses, microbial strains, mutant animal
strains, cell lines, antibodies, and similarmaterials described in
the article are available from a national collection or will be
made available in a timely fashion, at reasonable cost, and in
limited quantities to members of the scientific community for
noncommercial purposes. The authors guarantee that they
have the authority to comply with this policy either directly or
by means of material transfer agreements through the owner.
Similarly, the authors agree to make available computer
programs, originating in the authors’ laboratory, that are the
only means of confirming the conclusions reported in the ar-
ticle but that are not available commercially. The program(s)
and suitable documentation regarding its (their) use may be
provided by any of the followingmeans: (i) as a program trans-
mitted via the Internet, (ii) as an Internet server-based tool, or
(iii) as a compiled or assembled form on a suitable medium. It
is expected that the material will be provided in a timely fash-
ion and at reasonable cost to members of the scientific com-
munity for noncommercial purposes. The authors guarantee
that they have the authority to comply with this policy either
directly or by means of material transfer agreements through
the owner.
Permissions. The corresponding author is responsible for
obtaining permission from both the original author and the
original publisher (i.e., the copyright owner) to reproduce or
modify figures (including maps) and tables and to reproduce
text (in whole or in part) from previous publications.
Permission(s) must be obtained no later than the modifica-
tion stage. The original signed permission(s) must be identi-
fied as to the relevant item in the ASMmanuscript (e.g., “per-
missions for Fig. 1 in JCM00123-14”) and submitted to the
ASM production editor on request. In addition, a statement
indicating that the material is being reprinted with permission
must be included in the relevant figure legend or table footnote
of the manuscript. Reprinted text must be enclosed in quota-
tion marks, and the permission statement must be included as
running text or indicated parenthetically.
It is expected that the authors will provide written assurance
that permission to cite unpublished data or personal commu-
nications has been granted. For supplemental material in-
tended for posting by ASM (see “Supplemental Material”), if
the authors of the JCM manuscript are not also the owners of
the supplemental material, the corresponding author must
send to ASM signed permission from the copyright owner that
allows posting of thematerial, as a supplement to the article, by
ASM. The corresponding author is also responsible for incor-
porating in the supplemental material any copyright notices
required by the owner.
Authorship. All authors of a manuscript must have agreed
to its submission and are responsible for its content (initial
submission and any subsequent versions), including appropri-
ate citations and acknowledgments, andmust also have agreed
that the corresponding author has the authority to act on their
behalf in all matters pertaining to publication of the manu-
script. The corresponding author is responsible for obtaining
such agreements and for informing the coauthors of the man-
uscript’s status throughout the submission, review, and publi-
cation process. Submitting a paper before all coauthors have
read and approved it is considered an ethical violation, as is
failure to credit someonewho qualifies as a coauthor; however,
ASM does not itself investigate or attempt to resolve author-
ship disputes.
An author is one whomade a substantial contribution to the
overall design and execution of the experiments; therefore,
ASM considers all authors responsible for the entire paper.
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reagents or critiqued the paper, need not be listed as authors
but may be recognized in the Acknowledgments section. ASM
does not permit “ghost authorship,” i.e., individuals who con-
tribute to the research, data analysis, and/or writing of an arti-
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Examples of ghost authors include medical writers and em-
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cution of the experiments.
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tium, or the like (e.g., the Active Bacterial Core Surveillance
Team) may be listed as a coauthor in the byline if its contrib-
uting members satisfy the requirements for authorship and
accountability as described in these Instructions. The names
(and institutional affiliations if desired) of the contributing
members only may be given as a separate paragraph in the
Acknowledgments section.
If the contributingmembers of the group associatedwith the
work do not fulfill the criteria of substantial contribution to
and responsibility for the paper, the groupmay not be listed in
the author byline. Instead, it and the names of its contributing
members may be listed in the Acknowledgments section.
All authors must agree to the order in which their names are
listed in the byline. Statements regarding equal contributions
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cluded in the Acknowledgments section.
A change in authorship (order of listing, addition or dele-
tion of a name, or corresponding author designation) after
submission of the manuscript will be implemented only after
receipt of signed statements of agreement from all parties in-
volved.
Disputes about authorship may delay or prevent review
and/or publication of the manuscript. Should the individuals
involved be unable to reach an accord, review and/or publica-
tion of the manuscript can proceed only after the matter is
investigated and resolved by the authors’ institution(s) and an
official report of such and signed statements of agreement are
provided to ASM.
Conflict of interest. All authors are expected to disclose, in
the manuscript submittal letter, any commercial affiliations as
well as consultancies, stock or equity interests, and patent-
licensing arrangements that could be considered to pose a con-
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hanced by the results presented. All funding sources for the
project, institutional and corporate, should be credited in the
Acknowledgments section, as described below. In addition, if a
manuscript concerns a commercial product, the manufacturer’s
namemust be indicated in theMaterials andMethods section or
elsewhere in the text, as appropriate, in an obvious manner.
Copyright
To maintain and protect the Society’s ownership and rights
and to continue to afford scientists the opportunity to publish
in high-quality journals, ASM requires the corresponding au-
thor to sign a copyright transfer agreement on behalf of all the
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In the copyright transfer agreement signed by an author,
ASM grants to that author (and coauthors) the right to repub-
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not be reprinted/posted without ASM’s prior written permis-
sion, however, as this would constitute duplicate publication.
Authors may post their own published articles on their per-
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similar) websites without ASM’s prior written permission pro-
vided that appropriate credit is given (i.e., the copyright lines
shown at the bottom of the first page).
Works authored solely by U.S. government employees are
not subject to copyright protection, so there is no copyright to
be transferred. However, the other provisions of the copyright
transfer agreement, such as author representations of original-
ity and authority to enter into the agreement, apply to U.S.
government employee-authors as well as to other authors.
When funds from theWellcome Trust or Research Councils
UK are used to pay an article open access fee, the article will be
published under the Creative Commons Attribution license
(CC-BY) in accordance with the funding organization’s open
access policies. Authors will be required to notify ASM and
complete the Author Warranty and Provisional License to
Publish at the time of submission.
Copyright for supplemental material (see “Supplemental
Material”) remains with the author, but a license permitting
the posting by ASM is included in the article copyright transfer
agreement. If the author of the article is not also the copyright
owner of the supplemental material, the corresponding author
must send to ASM signed permission from the owner that
allows posting of thematerial, as a supplement to the article, by
ASM. The corresponding author is also responsible for incor-
porating into the supplemental material any copyright notices
required by the owner.
Funding Agency Repositories
The National Institutes of Health (NIH) requests that its
grantee and intramural authors provide copies of their ac-
cepted manuscripts to PubMed Central (PMC) for posting in
the PMCPublic Access Repository. However, JCM authors are
automatically in compliance with this policy and need take no
action themselves. For the past several years, ASM has depos-
ited in PubMedCentral all publications from all ASM journals.
Further, ASM policy is that all primary research articles are
made available to everyone, free, 6 months after publication
through PubMed Central, HighWire, and international
PubMed Central-like repositories. By having initiated these
policies, ASM is in full compliance with NIH policy. For more
information, see http://publicaccess.nih.gov/. ASM also allows
JCM authors whose work was supported by funding agencies
that have public access requirements like those of the NIH
(e.g., the Wellcome Trust) to post their accepted manuscripts
in publicly accessible electronic repositories maintained by
those funding agencies. If a funding agency does not itself
maintain such a site, then ASM allows the author to fulfill that
requirement by depositing the manuscript (not the typeset ar-
ticle) in an appropriate institutional or subject-based open re-
pository established by a government or noncommercial en-
tity.
Since ASMmakes the final, typeset articles from its primary-
research journals available free of charge on the ASM Journals
and PMC websites 6 months after final publication, ASM re-
quests that when submitting the accepted manuscript to PMC
or a similar public access site, the author specify that the post-
ing release date for the manuscript be no earlier than 6
months after publication of the typeset article by ASM and
that a link to the published manuscript on the journal web-
site be provided.
Use of Human Subjects or Animals in Research
The use of human subjects or animals for research purposes
is regulated by the federal government and individual institu-
tions. Authors of manuscripts describing research involving
human subjects or animal experimentation must obtain
approval from their Institutional Review Board (IRB) or Insti-
tutional Animal Care andUse Committee (IACUC), as appro-
priate, prior to manuscript submission. Authors of manu-
scripts that describe multisite research must obtain approval
from each institution’s IRB or IACUC, as appropriate. A state-
ment of IRB or IACUC approval must be included in the
Materials and Methods section. Documentation of IRB or
IACUC status must be made available upon request.
Patient Identiﬁcation
To protect the privacy of individuals mentioned in clinical
studies, in case histories, and as sources of isolates, do not
identify them by their initials, even as part of a strain designa-
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tion. Change the initials to numerals or use randomly chosen
letters. Do not give hospital unit numbers; if a designation is
needed, use only the last two digits of the unit. (Note: estab-
lished designations of some viruses and cell lines, although
they consist of initials, are acceptable [e.g., JC virus, BK virus,
and HeLa cells].)
Provision of Requisite Information for Molecular
Applications
Authors of manuscripts which contain quantitative real-time
PCR applications are encouraged to consult the article con-
cerning minimum information for publication of quantitative
real-time PCR experiments (theMIQE guidelines) by Bustin et
al. (Clin. Chem. 55:611–622, 2009) for guidance as to what
information should be considered for inclusion in their sub-
mission.
Newly determined nucleotide and/or amino acid sequence
data must be deposited and GenBank/ENA/DDBJ accession
numbers must be included in the manuscript no later than the
modification stage of the review process. It is expected that the
sequence data will be released to the public no later than the
publication (online posting) date of the accepted manuscript.
The accession numbers should be included in a separate para-
graph at the end of the Materials and Methods section for
full-length papers or at the end of the text for Short-Form
papers. If conclusions in amanuscript are based on the analysis
of sequences and a GenBank/ENA/DDBJ accession number is
not provided at the time of the review, authors should provide
the annotated sequence data as supplemental material for in-
formation only.
It is expected that when previously published sequence ac-
cession numbers are cited in a manuscript, the original cita-
tions (e.g., journal articles) will be included in the References
section when possible or reasonable.
Authors are also expected to do elementary searches and
comparisons of nucleotide and amino acid sequences against
the sequences in standard databases (e.g., GenBank) immedi-
ately before manuscripts are submitted and again at the proof
stage.
Analyses should specify the database, and the date of each
analysis should be indicated as, e.g., January 2014. If relevant,
the version of the software used should be specified.
See “Presentation of Nucleic Acid Sequences” for nucleic
acid sequence formatting instructions.
The URLs of the databases mentioned above are as follows:
DNA Data Bank of Japan (DDBJ), http://www.ddbj.nig.ac.jp/;
ENA (European Nucleotide Archive), http://www.ebi.ac.uk
/ena/; andGenBank, National Center for Biotechnology Infor-
mation, http://www.ncbi.nlm.nih.gov/.
Proper Use of Locus Tags as Systematic Identiﬁers
for Genes
To comply with recommendations from the International Nu-
cleotide Sequence Database (INSD) Collaborators and to
avoid conflicts in gene identification, researchers should im-
plement the following two fundamental guidelines as stan-
dards for utilization of locus tags in genome analysis, annota-
tion, submission, reporting, and publication. (i) Locus tag
prefixes are systematic gene identifiers for all of the replicons of
a genome and as such should be associated with a single ge-
nome project submission. (ii) New genome projects must be
registered with the INSD, and new locus tag prefixes must be
assigned in cooperation with the INSD to ensure that they
conform to the agreed-upon criteria.
Structural Determinations
Coordinates for new structures of macromolecules must be
deposited in the Protein Data Bank and assigned identification
codes must be included in the manuscript no later than the
modification stage of the review process. It is expected that the
coordinates will be released to the public no later than the
publication (online posting) date of the accepted manuscript.
Authors are encouraged to send coordinates with their original
submission, however, so that reviewers can examine them
alongwith themanuscript. The accession number(s) should be
listed in a separate paragraph at the end of the Materials and
Methods section for full-length papers or at the end of the text
for Short-Form papers.
The URLs for coordinate deposition are http://rcsb-deposit
.rutgers.edu/ and http://pdbdep.protein.osaka-u.ac.jp/en/.
Microarray Data
The entire set of supportingmicroarray datamust be deposited
in the appropriate public database (e.g., GEO,ArrayExpress, or
CIBEX) and the assigned accession number(s) must be in-
cluded in the manuscript no later than the modification stage
of the review process. It is expected that the data will be re-
leased to the public no later than the publication (online post-
ing) date of the accepted manuscript. Authors are encouraged
to send the relevant data with their original submission, how-
ever, so that reviewers can examine them along with the man-
uscript. The accession number(s) should be listed in a separate
paragraph at the end of the Materials and Methods section for
full-length papers or at the end of the text for Short-Form
papers.
The URLs of the databases mentioned above are as follows:
Gene ExpressionOmnibus (GEO), http://www.ncbi.nlm.nih.gov
/geo/; ArrayExpress, http://www.ebi.ac.uk/arrayexpress/; and Cen-
ter for Information Biology Gene Expression Database
(CIBEX), http://cibex.nig.ac.jp/data/index.html.
Culture Deposition
JCM expects authors to deposit important strains in publicly
accessible culture collections and to refer to the collections and
strain numbers in the text. Since the authenticity of subcul-
tures of culture collection specimens that are distributed by
individuals cannot be ensured, authors should indicate labo-
ratory strain designations and donor sources as well as original
culture collection identification numbers.
MycoBank
New scientific names of fungi along with key nomenclatural
and descriptive material must be deposited in MycoBank
(http://www.mycobank.org) and the assigned accession num-
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ber(s) must be included in the manuscript no later than the
modification stage of the review process. It is expected that the
data will be released to the public no later than the publication
(online posting) date of the accepted manuscript. Authors are
encouraged to send the relevant data with their original sub-
mission, however, so that reviewers can examine them along
with themanuscript. The accession number(s) should be listed
in a separate paragraph at the end of the Materials and Meth-
ods section for full-length papers or at the end of the text for
Short-Form papers.
Supplemental Material
Supplemental material will be peer reviewed along with the
manuscript and must be uploaded to the eJournalPress (eJP)
peer review system at initial manuscript submission. The deci-
sion to publish the material online with the accepted article is
made by the editor. It is possible that a manuscript will be
accepted but that the supplemental material will not be.
The number of supplemental material files is limited to 10.
Supplemental files should be submitted in the following stan-
dard formats.
• Text, figures, tables, and legends should be included
in a single PDF file. All figures and tables should be
numbered independently and cited at the relevant
point in the manuscript text, e.g. “Fig. S1,” “Fig. S2,”
“Table S3,” etc. Do not duplicate data by presenting
them in both the text and the figure. Each legend
should appear below its corresponding figure or table.
Themaximumfile size is 8MB. Please review this sam-
ple file for guidance.
• Data set (Excel [.xls]) files should include a brief de-
scription of how the data are used in the paper. The
maximum file size is 8 MB. Please review this sample
file for guidance.
• Movies (Audio Video Interleave [.avi], QuickTime
[.mov], or MPEG files) should be submitted at the de-
sired reproduction size and length and should be ac-
companied by a legend. The maximum file size is 20
MB.
Unlike the manuscript, supplemental material will not
be edited by the ASM Journals staff and proofs will not be
made available. References related to supplementalmaterial
only should not be listed in the References section of an
article; instead, include them with the supplemental mate-
rial. Supplemental material will always remain associated
with its article and is not subject to any modifications after
publication.
Material that has been published previously (print or on-
line) is not acceptable for posting as supplemental material.
Instead, the appropriate reference(s) to the original publica-
tion should be made in the manuscript.
Copyright for the supplemental material remains with the
author, but a license permitting posting by ASMmust be signed
by the corresponding author. If you are not the copyright owner,
youmust provide toASMsigned permission from the owner that
allows posting of the material, as a supplement to your article,
by ASM. You are responsible for including in the supplemental
material any copyright notices required by the owner.
See also “Publication Fees.”
Warranties and Exclusions
Articles published in this journal represent the opinions of the
authors and do not necessarily represent the opinions of ASM.
ASM does not warrant the fitness or suitability, for any purpose,
of any methodology, kit, product, or device described or iden-
tified in an article. The use of trade names is for identification
purposes only and does not constitute endorsement by ASM.
SUBMISSION, REVIEW, AND PUBLICATION PROCESSES
Submission Process
All submissions to JCM must be made electronically via the
eJournalPress (eJP) online submission and peer review system
at the following URL: http://jcm.msubmit.net/cgi-bin/main
.plex. (E-mailed submissions will not be accepted.) First-time
users must create an Author account, which may be used for
submitting to all ASM journals. Instructions for creating an
Author account are available at the aboveURL via the “help for
authors” link, and step-by-step instructions for submitting a
manuscript via eJP are also available through the same link on
the log-in screen or on the account holder’s Home page. Infor-
mation on file types acceptable for electronic submission can
be found under the Files heading in the help for authors screen.
Review Process
All manuscripts are considered to be confidential and are re-
viewed by the editors, members of the editorial board, or qual-
ified ad hoc reviewers.
To expedite the review process, authorsmust recommend at
least three editorial board members who have expertise in the
field, who are not members of their institution(s), who have
not recently been associated with their laboratory(ies), and
who could not otherwise be considered to pose a conflict of
interest regarding the submitted manuscript.
Copies of in-press and submittedmanuscripts that are im-
portant for judgment of the present manuscript should be
included as supplemental material for information only to
facilitate the review.
When a manuscript is submitted to the journal, it is given a
control number (e.g., JCM00123-14) and assigned to one of
the editors. (Always refer to this control number in commu-
nications with the editor and the Journals Department.) It is
the responsibility of the corresponding author to inform the
coauthors of themanuscript’s status throughout the submission,
review, and publication processes. The reviewers operate under
strict guidelines set forth in “Guidelines for Reviewers” (http:
//www.journals.asm.org/site/misc/reviewguide.xhtml) and are
expected to complete their reviews expeditiously.
The corresponding author is notified, generally within 4 to 6
weeks after submission, of the editor’s decision to accept, re-
ject, or require modification. When modification is requested,
the corresponding author must either submit the modified
version within 2months or withdraw themanuscript. A point-
by-point response to the reviews must be loaded as a separate
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file (identified as such), and a compare copy of the manuscript
(without figures) should be included as a Marked Up Manu-
script if the editor requested one.
Manuscripts that have been rejected, or withdrawn after be-
ing returned formodification, may be resubmitted to the same
ASM journal if the major criticisms have been addressed. A
manuscript rejected by one ASM journal on scientific grounds
or on the basis of its general suitability for publication is con-
sidered rejected by all other ASM journals; however, a manu-
script rejected solely on the basis of scope may be “resubmit-
ted” to a more appropriate ASM journal.
For all resubmissions (to the same or a different journal,
irrespective of the extent of the revisions and irrespective of the
amount of time between rejection and resubmission), the
cover letter must state that the manuscript is a resubmission,
and the formermanuscript control numbermust be provided.
A point-by-point response to the review(s)must be loaded as a
separate file (identified as such), and a compare copy of the
revised manuscript showing all changes must be included as a
Marked UpManuscript. Manuscripts resubmitted to the same
journal are normally handled by the original editor.
Rejected manuscripts may be resubmitted only once unless
permission has been obtained from the original editor or from
the editor in chief.
Notiﬁcation of Acceptance
When an editor has decided that amanuscript is acceptable for
publication on the basis of scientific merit, the author and the
Journals Department are notified. A PDF version of the ac-
cepted manuscript is posted online as soon as possible (see
“JCM Accepts”).
The text files undergo an automated preediting, cleanup,
and tagging process specific to the particular article type, and
the illustrations are examined. If all files have been prepared
according to the criteria set forth in these Instructions and
those in the eJP online manuscript submission system, the ac-
ceptance procedure will be completed successfully. If there are
problems that would cause extensive corrections to bemade at
the copyediting stage or if the files are not acceptable for pro-
duction, ASM Journals staff will contact the corresponding
author. Once all thematerial intended for publication has been
determined to be adequate, themanuscript is scheduled for the
next available issue. The editorial staff of the ASM Journals
Department completes the editing of themanuscript to bring it
into conformity with prescribed standards.
JCM Accepts
For its primary-research journals, ASM posts online PDF ver-
sions of manuscripts that have been peer reviewed and ac-
cepted but not yet copyedited. This feature is called “[journal
acronym] Accepts” (e.g., JCM Accepts) and is accessible from
the Journals website. The manuscripts are published online as
soon as possible after acceptance, on a weekly basis, before the
copyedited, typeset articles are published. They are posted “as
is” (i.e., as submitted by the authors at the modification stage)
and do not reflect ASM editorial changes. No corrections/
changes to the PDF manuscripts are accepted. Accordingly,
there likely will be differences between the JCM Accepts man-
uscripts and the final, typeset articles. Themanuscripts remain
listed on the JCM Accepts page until the final, typeset articles
are posted. At that point, the manuscripts are removed from
the JCM Accepts page. The manuscripts are under subscrip-
tion access control until 6 months after the typeset articles are
posted, when free access is provided to everyone (subject to the
applicable ASM license terms and conditions). Supplemental
material intended, and accepted, for publication is not posted
until publication of the final, typeset article.
The ASM embargo policy allows a press release to be issued
as soon as the ahead-of-print manuscript is posted on the JCM
Accepts page. To be notified as soon as your manuscript is
posted, please sign up for e-Alerts at http://jcm.asm.org/cgi
/alerts.
Instructions on how to cite such manuscripts may be found
in “References.”
Page Proofs
Page proofs, together with a query sheet and instructions for
handling proofs, will be made available to the corresponding
author electronically. Queries must be answered on the query
page, and any changes related to the queries must be indicated
on the proofs. Note that the copy editor does not query at every
instance where a change has been made. Queries are written
only to request necessary information or clarification of an
unclear passage or to draw attention to edits that may have
altered the sense. It is the author’s responsibility to read the
entire text, tables, and figure legends, not just items queried.
Corrected proofs must be returned within 48 hours after noti-
fication of availability.
The proof stage is not the time to make extensive correc-
tions, additions, or deletions. Figures as they appear in the
proofs are for validation of content and placement, not quality
of reproduction or color accuracy. Print output of figures in
the PDF page proofs will be of lower quality than the same
figures viewed on a monitor. Please avoid making changes to
figures based on quality of color or reproduction in proof.
Important new information that has become available be-
tween acceptance of the manuscript and receipt of the proofs
may be inserted as an addendum in proof with the permission
of the editor. If references to unpublished data or personal
communications are added, it is expected that written assur-
ance granting permission for the citation will be included.
Limit changes to correction of spelling errors, incorrect data,
and grammatical errors and updated information for refer-
ences to articles that have been submitted or are in press. If
URLs have been provided in the article, recheck the sites to
ensure that the addresses are still accurate and thematerial that
you expect the reader to find is indeed there.
Questions about late proofs and problems with the proofs
should be directed to the ASM Journals Department (e-mail,
cbrown@asmusa.org; telephone, 202-942-9384).
PDF Files
A corresponding author who has included an e-mail address in
his/her “corresponding author” footnote will have limited ac-
cess (10 downloads, total) to the PDF file of his/her published
article. An e-mail alert will automatically be sent to him/her on
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the day the issue is posted. It will provide a URL, which will be
required to obtain access, and instructions. An article may be
viewed, printed, or stored, provided that it is for the author’s
own use.
Should coauthors or colleagues be interested in viewing the
paper for their ownuse, the corresponding authormay provide
themwith the URL; a copy of the article may not be forwarded
electronically. However, theymust bemade aware of the terms
and conditions of the ASM copyright. (For details, go to http:
//www.journals.asm.org/site/misc/terms.xhtml.) Note that
each such download will count toward the corresponding au-
thor’s total of 10. After 10 downloads, access will be denied and
can be obtained only through a subscription to the journal
(either individual or institutional) or after the standard access
control has been lifted (i.e., 6 months after publication).
Publication Fees
Page charges. Authors whose research was supported by
grants, special funds (including departmental and institu-
tional), or contracts (including governmental) or whose re-
search was done as part of their official duties (government or
corporate, etc.) are required to pay page charges (based on the
number of typeset pages, including illustrations, in the article).
Corresponding authors of articles accepted for publicationwill
receive an e-mail notifying themhow topay page and any other
applicable publication charges (see below).
For a corresponding author who is an active member of
ASM at the Contributing or Premium level, page charges are
$67 per page for the first eight pages and $125 per page for each
page in excess of eight (subject to change without notice).
For a nonmember or Supporting member corresponding
author, page charges are $135 per page for the first eight pages
and $250 for each page in excess of eight (subject to change
without notice). Nonmember corresponding authors or Sup-
porting members may join ASM and renew or upgrade mem-
bership online to obtain discounts on publication fees.
If the research was not supported by any of the means
described above, a request to waive the charges may be sent
to the Journals Department, ASM, 1752 N St., N.W., Wash-
ington, DC 20036-2904, USA (fax, 202-942-9355; e-mail,
cbrown@asmusa.org [after acceptance of the manuscript]).
The request must include the manuscript control number as-
signed by ASM and indicate how the work was supported.
Waivers apply only to page charges; responsibility for color
charges and other publication fees remains with the author.
Minireviews, Commentaries, PhotoQuizzes, andComment
Letters to the Editor are not subject to page charges. New-Data
Letters to the Editor are subject to page charges.
Color charges. The cost of publishing in color must be
borne by the author.
For a corresponding author who is an active member of
ASM at the Contributing or Premium level, color charges are
$170 per color figure (subject to change without notice).
For a nonmember or Supporting member corresponding
author, color charges are $375 per color figure (subject to
change without notice). Nonmember corresponding authors
or Supporting members may join ASM and renew or upgrade
membership online to obtain discounts on publication fees.
Minireviews, Commentaries, PhotoQuizzes, andComment
Letters to the Editor are not subject to color charges. New-Data
Letters to the Editor are subject to color charges.
Author reprints and eprints. Reprints (in multiples of
100) and eprints (downloadable PDFs) may be purchased by
all coauthors. In addition to the 10 free published PDF files
mentioned above, the corresponding authors of Minireviews
may receive 100 free eprints of their contribution and the cor-
responding authors of Commentaries may receive 50 free
eprints. Instructions for ordering gratis or additional reprints
and eprints can be found in the billing notification e-mail sent
to all corresponding authors. To order reprints postpublica-
tion, please follow the instructions on the Author Reprint Or-
der Form. Please contact cjsreprints@cadmus.com with any
questions.
Supplemental material fee. Authors are charged a flat fee
for posting supplemental material as an adjunct to their pub-
lished article. (Exception: no fee is charged for supplemental
material associated with Minireviews or Commentaries.)
For a corresponding author who is an active member of
ASMat theContributing or Premium level, the supplemental
material fee is $190. For a nonmember or Supporting mem-
ber corresponding author, the supplemental material fee is
$285. Nonmember corresponding authors or Supporting
members may join ASM and renew or upgrade membership
online to obtain discounts on publication fees.
Optional open access fee. Author-paid optional open ac-
cess (OOA) is now available for all article types. For a corre-
sponding author who is an active member of ASM at the
Contributing or Premium level, the OOA fee is $2,000. For a
nonmember or Supporting member corresponding author,
the OOA fee is $3,000. Nonmember corresponding authors or
Supporting members may join ASM and renew or upgrade
membership online to obtain discounts on publication fees.
These fees are in addition to any page charges, color charges, or
supplemental material charges and permit immediate public
access to both the preliminary “Accepts” version and the copy-
edited, typeset version published in the online journal. This
option includes immediate open access provided through
NIH’s PubMed Central repository; all primary research pub-
lished in ASM journals is freely available through PubMed
Central 6 months after publication.
When funds from theWellcome Trust or Research Councils
UK are used to pay an article open access fee, the article will be
published under the Creative Commons Attribution license
(CC-BY) in accordance with the funding organization’s open
access policies. Authors will be required to notify ASM and
complete the Author Warranty and Provisional License to
Publish at the time of submission.
ORGANIZATION AND FORMAT
Editorial Style
The editorial style of ASM journals conforms to the ASM Style
Manual for Journals (American Society for Microbiology,
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2014, in-house document) and How To Write and Publish a
Scientific Paper, 7th ed. (Greenwood, Santa Barbara, CA,
2011), as interpreted andmodified by the editors and the ASM
Journals Department.
The editors and the Journals Department reserve the privi-
lege of editing manuscripts to conform with the stylistic con-
ventions set forth in the aforesaid publications and in these
Instructions.
On receipt at ASM, an accepted manuscript undergoes an
automated preediting, cleanup, and tagging process specific to
the particular article type. To optimize this process, manu-
scripts must be supplied in the correct format and with the
appropriate sections and headings.
Type every portion of the manuscript double-spaced (a
minimum of 6 mm between lines), including figure legends,
table footnotes, and References, and number all pages in se-
quence, including the abstract, figure legends, and tables. Place
the last two items after the References section. Manuscript
pages must have continuous line numbers and page numbers.
Manuscripts without line and page numbers will be returned
to authors for provision of this information prior to process-
ing. The font size should be no smaller than 12 points. It is
recommended that the following sets of characters be easily
distinguishable in the manuscript: the numeral zero (0) and
the letter “oh” (O); the numeral one (1), the letter “el” (l), and
the letter “eye” (I); and amultiplication sign () and the letter
“ex” (x). Do not create symbols as graphics or use special fonts
that are external to your word processing program; use the
“insert symbol” function. Set the page size to 8.5 by 11 inches
(ca. 21.6 by 28 cm). Italicize any words that should appear in
italics, and indicate paragraph lead-ins in boldface type.
Manuscripts may be editorially rejected, without review,
on thebasis of poorEnglish or lackof conformity to the stan-
dards set forth in these Instructions.
Authors who are unsure of proper English usage should
have their manuscripts checked by someone proficient in the
English language or engage a professional language editing ser-
vice for help.
Manuscript Submission Checklist
• Double-space all text, including references and figure
legends.
• Number pages.
• Number lines continuously.
• Present statistical treatment of data where appropriate.
• Format references in ASM style.
• Provide accession numbers for all newly published se-
quences in a dedicated paragraph, and if a sequence or
sequence alignment important for evaluation of the
manuscript is not yet available, provide the informa-
tion as supplemental material for information only or
make the material available on a website for access by
the editor and reviewers.
• Confirm that genetic and chemical nomenclature con-
forms to instructions.
• Include as supplemental material for information only
in-press and submittedmanuscripts that are important
for judgment of the present manuscript.
Full-Length Papers
Full-length papers include the elements described in this sec-
tion.
Title, running title, and byline. Each manuscript should
present the results of an independent, cohesive study; thus,
numbered series titles are not permitted. Exercise care in com-
posing a title. Avoid the main title/subtitle arrangement, com-
plete sentences, and unnecessary articles. On the title page in-
clude the title, the running title (not to exceed 54 characters
and spaces), the name of each author, all authors’ affiliations at
the time theworkwas performed, and a footnote indicating the
present address(es) of any author(s) no longer at the institu-
tion where the work was performed. Place a number sign (#)
after the name of the author to whom inquiries regarding the
paper should be directed (see “Correspondent footnote,” be-
low). Please review this sample title page for guidance.
Study group in byline. A study group, surveillance team,
working group, consortium, or the like (e.g., the Active Bacte-
rial Core Surveillance Team)may be listed as a coauthor in the
byline if its contributing members satisfy the requirements for
authorship and accountability as described in these Instruc-
tions. The names (and institutional affiliations if desired) of
the contributing members may be given as a separate para-
graph in Acknowledgments.
If the contributingmembers of the group associatedwith the
work do not fulfill the criteria of substantial contribution to
and responsibility for the paper, the groupmay not be listed in
the author byline. Instead, it and the names of its contributing
members may be listed in the Acknowledgments section.
Correspondent footnote. The e-mail address for the cor-
responding author should be included on the title page of the
manuscript. This informationwill be published in the article as
a footnote to facilitate communication and will be used to no-
tify the corresponding author of the availability of proofs and,
later, of the PDF file of the published article. Nomore than two
authors may be designated corresponding authors.
Abstract. Limit the abstract to 250words or fewer and con-
cisely summarize the basic content of the paper without pre-
senting extensive experimental details. Avoid abbreviations
and references, and do not include diagrams.When it is essen-
tial to include a reference, use the same format as shown for the
References section but omit the article title. Conclude the ab-
stract with a summary statement. Because the abstract will be
published separately by abstracting services, it must be com-
plete and understandable without reference to the text.
Introduction. The introduction should supply sufficient
background information to allow the reader to understand and
evaluate the results of the present study without referring to
previous publications on the topic. The introduction should
also provide the hypothesis that was addressed or the rationale
for the present study. Choose references carefully to provide
the most salient background rather than an exhaustive review
of the topic.
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Case Report. The Case Report section, placed after the in-
troduction and before Materials and Methods, is optional and
gives relevant clinical information about one or more patients
while being incidental to the rest of the paper. (If the Case
Report constitutes the entire article, the paper must be pre-
sented in Case Report format [see “Case Reports,” below],
which differs from that used for a full-length text or a Short-
Form paper.)
Materials and Methods. The Materials and Methods sec-
tion must include sufficient technical information to allow the
experiments to be repeated. The sources of all media (i.e.,
name and location of manufacturer) or components of a new
formulation must be provided. When centrifugation condi-
tions are critical, give enough information to enable another
investigator to repeat the procedure: make of centrifuge,
model of rotor, temperature, time at maximum speed, and
centrifugal force ( g rather than revolutions perminute). For
commonly used materials and methods (e.g., media and pro-
tein concentration determinations), a simple reference or spe-
cifically recommended product or procedure is sufficient. If
several alternative methods are commonly used, it is helpful to
identify the method briefly as well as to cite the reference. For
example, it is preferable to state “cells were broken by ultra-
sonic treatment as previously described (9)” rather than to
state “cells were broken as previously described (9).” This al-
lows the reader to assess the method without constant refer-
ence to previous publications. Describe new methods com-
pletely, and give sources of unusual chemicals, reagents,
equipment, or microbial strains. When large numbers of mi-
crobial strains or mutants are used in a study, include tables
identifying the immediate sources (i.e., sources from whom
the strains were obtained) and properties of the strains, mu-
tants, bacteriophages, and plasmids, etc.
A method or strain, etc., used in only one of several experi-
ments reported in the paper may be described in the Results
section or very briefly (one or two sentences) in a table foot-
note or figure legend. It is expected that the sources from
whom the strains were obtained will be identified.
Results. In the Results section, include the rationale or de-
sign of the experiments as well as the results; reserve extensive
interpretation of the results for the Discussion section. Present
the results as concisely as possible in one of the following: text,
table(s), or figure(s). Avoid extensive use of graphs to present
data which might be more concisely presented in the text or
tables. For example, except in unusual cases, double-reciprocal
plots used to determine apparentKm values should not be pre-
sented as graphs; instead, the values should be stated in the
text. Similarly, graphs illustrating other methods commonly
used to derive kinetic or physical constants (e.g., reduced-vis-
cosity plots and plots used to determine sedimentation veloc-
ity) need not be shown except in unusual circumstances. All
tabular datamust be accompanied by either standard deviation
values or standard errors of the means. The number of repli-
cate determinations (or animals) used for making such calcu-
lations must also be included. All statements concerning the
significance of the differences observed should be accompa-
nied by probability values given in parentheses. The statistical
procedure used should be stated in Materials and Methods.
Limit illustrations (particularly photomicrographs and elec-
tron micrographs) to those that are absolutely necessary to
show the experimental findings. Number figures and tables in
the order in which they are cited in the text, and be sure to cite
all figures and tables.
Discussion. The Discussion section should provide an in-
terpretation of the results in relation to previously published
work and to the experimental system at hand. It must not con-
tain extensive repetition of the Results section or reiteration of
the introduction. In short papers, the Results and Discussion
sections may be combined.
Acknowledgments. The source of any financial support
received for the work being publishedmust be indicated in the
Acknowledgments section. (It will be assumed that the absence
of such an acknowledgment is a statement by the authors that
no support was received.) The usual format is as follows: “This
work was supported by Public Health Service grant CA-01234
from the National Cancer Institute.”
Recognition of personal assistance should be given as a sep-
arate paragraph, as should any statements disclaiming en-
dorsement or approval of the views reflected in the paper or of
a product mentioned therein.
Appendixes. Appendixes that contain additional material
to aid the reader are permitted. Titles, authors, and reference
sections that are distinct from those of the primary article are
not allowed. If it is not feasible to list the author(s) of the
appendix in the byline or the Acknowledgments section of the
primary article, rewrite the appendix so that it can be consid-
ered for publication as an independent article, either full-
length paper or Short-Form style. Equations, tables, and fig-
ures should be labeled with the letter “A” preceding the
numeral to distinguish them from those cited in themain body
of the text.
References. In the reference list, references are numbered
in the order in which they are cited in the article (citation-
sequence reference system); ASM no longer uses the citation-
name system with an alphabetized reference list. In the text,
references are cited parenthetically by number in sequential
order. Data that are not published or not peer reviewed are
simply cited parenthetically in the text (see section ii below).
(i) References listed in the References section. The follow-
ing types of references must be listed in the References section:
• Journal articles (both print and online)
• Books (both print and online)
• Book chapters (book title is required)
• Patents
• Theses and dissertations
• Published conference proceedings
• Meeting abstracts (from published abstract books or
journal supplements)
• Letters (to the editor)
• Company publications
Instructions to Authors
10 January 2014, Instructions to Authors Journal of Clinical Microbiology jcm.asm.org
• In-press journal articles, books, and book chapters
(publication title is required)
Provide the names of all the authors and/or editors for each
reference; names should not be abbreviated with “et al.”
Since title and byline information that is downloaded from
PubMed does not always show accents, italics, or special char-
acters, authors should refer to the PDF files or hard-copy ver-
sions of the articles and incorporate the necessary corrections
in the submitted manuscript. Abbreviate journal names ac-
cording to the PubMed Journals Database (National Library of
Medicine, National Institutes of Health; available at http:
//www.ncbi.nlm.nih.gov/nlmcatalog/journals), the primary
source for ASM style.
Follow the styles shown in the examples below for print
references.
1. Caserta E, Haemig HAH, Manias DA, Tomsic J, Grundy
FJ, Henkin TM, Dunny GM. 2012. In vivo and in vitro
analyses of regulation of the pheromone-responsive prgQ
promoter by the PrgX pheromone receptor protein. J.
Bacteriol. 194:3386–3394.
2. Falagas ME, Kasiakou SK. 2006. Use of international
units when dosing colistin will help decrease confusion
related to various formulations of the drug around the
world. Antimicrob. Agents Chemother. 50:2274–2275.
(Letter.) {“Letter” or “Letter to the editor” is allowed but not
required at the end of such an entry.}
3. Cox CS, Brown BR, Smith JC. J. Gen. Genet., in press.*
{Article title is optional; journal title is mandatory.}
4. daCostaMS, NobreMF, Rainey FA. 2001. Genus I. Ther-
mus Brock and Freeze 1969, 295,AL emend. Nobre, Tru¨per
and da Costa 1996b, 605, p 404–414. In Boone DR, Cas-
tenholz RW, Garrity GM (ed), Bergey’s manual of system-
atic bacteriology, 2nd ed, vol 1. Springer, New York, NY.
5. Stratagene. 2006. Yeast DNA isolation system: instruction
manual. Stratagene, La Jolla, CA. {Use the company name
as the author if none is provided for a company publication.}
6. Forman MS, Valsamakis A. 2011. Specimen collection,
transport, and processing: virology, p 1276–1288. In Ver-
salovic J, Carroll KC, Jorgensen JH, Funke G, Landry ML,
Warnock DW (ed), Manual of clinical microbiology, 10th
ed, vol 2. ASM Press, Washington, DC.
7. Fitzgerald G, Shaw D. InWaters AE (ed), Clinical micro-
biology, in press. EFH Publishing Co, Boston, MA.*
{Chapter title is optional.}
8. Garcı´a CO, Paira S, BurgosR,Molina J,Molina JF, Calvo
C, Vega L, Jara LJ, Garcı´a-Kutzbach A, Cuellar ML,
Espinoza LR. 1996. Detection of SalmonellaDNA in syno-
vial membrane and synovial fluid from Latin American
patients using the polymerase chain reaction. Arthritis
Rheum. 39(Suppl 9):S185. {Meeting abstract published in
journal supplement.}
9. Carlson E. 2013. Selective penicillin-binding protein im-
aging probes reveal substructure in bacterial cell division,
p 59. Final Program 113thGen.Meet. Am. Soc.Microbiol.
American Society for Microbiology, Washington, DC.
{Abstract title is optional.}
10. Rotimi VO, Salako NO, Mohaddas EM, Philip LP. 2005.
Abstr. 45th Intersci. Conf. Antimicrob. Agents Che-
mother., abstr D-1658. {Abstract title is optional.}
11. Green PN, Hood D, Dow CS. 1984. Taxonomic status of
some methylotrophic bacteria, p 251–254. In Crawford
RL, Hanson RS (ed),Microbial growth on C1 compounds.
Proceedings of the 4th International Symposium. Ameri-
can Society for Microbiology, Washington, DC.
12. O’Malley DR. 1998. Ph.D. thesis. University of California,
Los Angeles, CA. {Title is optional.}
13. Odell JC. April 1970. Process for batch culturing. US pat-
ent 484,363,770. {Include the name of the patented item/
process if possible; the patent number is mandatory.}
14. Elder BL, Sharp SE. 2003. Cumitech 39, Competency as-
sessment in the clinical laboratory. Coordinating ed,
Sharp SE. ASM Press, Washington, DC.
*A reference to an in-press ASM publication should state the
control number (e.g., JCM00123-14) if it is a journal article or
the name of the publication if it is a book.
Online-only references must provide essentially the same
information that print references do. For online journal arti-
cles, posting or revision dates may replace the year of publica-
tion; a DOI (preferred) or URL is required for articles with
nontraditional page numbers or electronic article identifiers.
1. Bina XR, Taylor DL, Vikram A, Ante VM, Bina JE. 2013.
Vibrio cholerae ToxR downregulates virulence factor pro-
duction in response to cyclo(Phe-Pro). mBio 4(5):e00366-
13. doi:10.1128/mBio.00366-13.
2. Winnick S, Lucas DO,Hartman AL, Toll D. 2005. How do
you improve compliance? Pediatrics 115:e718–e724. doi:
10.1542/peds.2004-1133.
3. DionneMS, Schneider DS. 2002. Screening the fruitfly im-
mune system. Genome Biol. 3:reviews1010-reviews1010.2.
doi:10.1186/gb-2002-3-4-reviews1010.
4. Gregory ST. 2 September 2009. Chapter 2.5.4, Structural
basis for the decoding mechanism. In Bo¨ck A, et al (ed),
EcoSal—Escherichia coli and Salmonella: cellular and mo-
lecular biology. ASM Press, Washington, DC. doi:
10.1128/ecosal.2.5.4. {Note that each chapter has its own
posting date.}
Note: a posting or accession date is required for any online
reference that is periodically updated or changed.
Citations of ASM Accepts manuscripts should look like the
following example.
WangGG, PasillasMP,KampsMP. 15May 2006. Persis-
tent transactivation by Meis1 replaces Hox function in
myeloid leukemogenesis models: evidence for co-occu-
pancy ofMeis1-Pbx andHox-Pbx complexes on promot-
ers of leukemia-associated genes. Mol. Cell. Biol. doi:
10.1128/MCB.00586-06.
Other journals may use different styles for their publish-
ahead-of-print manuscripts, but citation entries must include
the following information: author name(s), posting date, title,
journal title, and volume and page numbers and/or DOI. The
following is an example:
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Zhou FX, Merianos HJ, Brunger AT, Engelman DM. 13
February 2001. Polar residues drive association of
polyleucine transmembrane helices. Proc. Natl. Acad. Sci.
U. S. A. doi:10.1073/pnas.041593698.
(ii) References cited in the text. References that should be
cited in the text include
• Unpublished data
• Manuscripts submitted for publication
• Unpublished conference presentations (e.g., a report
or poster that has not appeared in published confer-
ence proceedings)
• Personal communications
• Patent applications and patents pending
• Computer software, databases, and websites
These references should be made parenthetically in the text as
follows:
. . . similar results (R. B. Layton and C. C. Weathers, un-
published data).
. . . system was used (J. L. McInerney, A. F. Holden, and
P. N. Brighton, submitted for publication).
. . . as described previously (M. G. Gordon and F. L. Ratt-
ner, presented at the Fourth Symposium on Food Mi-
crobiology, Overton, IL, 13 to 15 June 1989). {For non-
published abstracts and posters, etc.}
. . . this new process (V. R. Smoll, 20 June 1999, Austra-
lian Patent Office). {For non-U.S. patent applications,
give the date of publication of the application.}
. . . available in the GenBank database (http://www.ncbi
.nlm.nih.gov/Genbank/index.html).
. . . using ABC software (version 2.2; Department of Mi-
crobiology, State University [http://www.state.micro
.edu]).
URLs for companies that produce any of the products men-
tioned in your study or for products being sold may not be
included in the article. However, company URLs that permit
access to scientific data related to the study or to shareware
used in the study are permitted.
(iii) Citations in abstracts. Because the abstract must be
able to stand apart from the article, references cited in it
should be clear without recourse to the References section. Use
an abbreviated form of citation, omitting the article title, as
follows.
(P. S. Satheshkumar, A. S.Weisberg, andB.Moss, J. Virol.
87:10700–10709, 2013, doi:10.1128/JVI.01258-13)
(J. H. Coggin, Jr., p. 93–114, in D. O. Fleming and D. L.
Hunt, ed., Biological Safety. Principles and Practices, 4th
ed., 2006)
“. . . in a recent report by D. A. Hopwood [mBio 4(5):
e00612-13, 2013, doi:10.1128/mBio00612-13] . . . .”
This style should also be used for Addenda in Proof.
(iv) References related to supplemental material. If refer-
encesmust be cited in the supplemental material, list them in a
separate References section within the supplemental material
and cite them by those numbers; do not simply include cita-
tions of numbers from the reference list of the associated arti-
cle. If the same reference(s) is to be cited in both the article
itself and the supplemental material, then that reference would
be listed in both References sections.
Short-Form Papers
The Short-Form format is intended for the presentation of
brief observations that do not warrant full-length papers.
However, Short-Form papers should contain firm data; obser-
vations alone are not acceptable. Submit Short-Form papers in
the same way as full-length papers. They receive the same re-
view, they are not published more rapidly than full-length pa-
pers, and they are not considered preliminary communica-
tions.
The title, running title (not to exceed 54 characters and
spaces), byline, and correspondent footnote should be pre-
pared as for a full-length paper. Each Short-Form paper must
have an abstract of no more than 50 words. Do not use section
headings in the body of the Short Form; combine methods,
results, and discussion in a single section. Paragraph lead-ins
are permissible. The text should be kept to a minimum and if
possible should not exceed 1,000 words; the number of figures
and tables should also be kept to a minimum. Materials and
methods should be described in the text, not in figure legends
or table footnotes. Present acknowledgments as in full-length
papers. The References section is identical to that of full-length
papers.
Minireviews
Minireviews are expected to be focused discussions of defined
topics relevant to clinical microbiologists. In general, they are
to be submitted only following invitation by the editor in chief
of JCM. Unsolicited Minireviews are discouraged. A topical
outline should be provided to the editor in chief for approval
prior to submission of the completed Minireview manuscript
in the eJP online manuscript submission and peer review sys-
tem.
Minireviews are not expected to be comprehensive reviews
of the literature but rather focused discussions of specific top-
ics. A standard title page should be provided. This is followed
by an abstract of 100 words or less and then the text of the
Minireview, which should not exceed 12 double-spaced man-
uscript pages in length, exclusive of tables, figures, photo-
graphs, and references. Up to three tables, figures, or photo-
graphs, total, may be included. References should be limited to
no more than 30. Minireviews will be reviewed by two JCM
editors, with the aim of expedited processing. In general, it is
hoped that, barring the necessity of major revisions, accepted
Minireviews will appear in print within 3 months of their sub-
mission and online ahead of print 6 to 8 weeks earlier.
Author bio. A short biographical sketch and photograph of
the one author most responsible for the minireview should be
submitted along with the initial version of the manuscript.
These will be published at the end of the article.
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• The text limit is 150 words and should include WHO
you are (your name), WHERE you received your edu-
cation,WHAT positions you have held and atWHICH
institutions, WHERE you are now (your current insti-
tution),WHY you have this interest, andHOWLONG
you have been in this area, as well as a brief review of
your scholarly interests and record of publication. In
addition, please list pertinent significant awards you
have received.
• The photo should be a recent black-and-white head
shot of passport size. It will be reduced to approxi-
mately 1.125 inches wide by 1.375 inches high. The
photo must meet the production criteria for regu-
lar figures and should be checked for production
quality by using Rapid Inspector, provided at the fol-
lowingURL: http://rapidinspector.cadmus.com/Rapid
Inspector/zmw/index.jsp.
• To submit, upload the text and photo with your man-
uscript in the submission and review system. Include
the biographical text immediately after the References
section of your manuscript, in the same file. It should
be labeled with the heading “Biosketch.” Upload the
head shot photograph in the submission system as a
“MinireviewBioPhoto”; include the author’snameor
enough of it for identification in the photo’s file
name.
Contact the scientific editor if you have questions about what
to write. Contact the production editor if you have questions
about submitting your files.
Commentaries
Commentaries are invited communications concerning topics
relevant to the readership of JCMand are intended to engender
discussion. Reviews of the literature, methods and other
how-to papers, and responses targeted at a specific published
paper are not appropriate. Commentaries are subject to re-
view.
The length may not exceed four printed pages, and the for-
mat is like that of a Minireview (see above) except that the
abstract is limited to 75 words.
Point-Counterpoint
Point-Counterpoint is a feature of JCM in which two experts
present opposing views on a contemporary issue in the labora-
tory diagnosis of infectious diseases. This feature will be the
lead article in the issue of JCM in which it appears. Participa-
tion as an author of a Point-Counterpoint feature is by invita-
tion only.
A JCMeditor will write a brief introductory piece of approx-
imately 200 words outlining why a specific issue is important
and then present the issue in the form of a question. The two
experts will then eachwrite a commentary, nomore than 1,000
words in length, in which they present evidence in support of
either the pro or con view. One table or one figure may be
included. Since these discussions will be evidence based, au-
thors may also cite up to 10 references. Unpublished or in-
press data which reflect the current practice in their laboratory
may be used but should not be the sole basis for their position.
Authors should send commentaries directly back to the JCM
editor within 30 days of receipt of the introductory statement.
Following receipt of both the pro and con commentaries, the
editor will review the submissions and may return them to the
author(s) with comments and/or suggested revisions. If revi-
sions are required, the author(s) will have 14 days to craft a
revised commentary, which will be sent directly back to the
editor.Upon receipt of final commentaries, the JCMeditorwill
write a brief summary consisting of no more than six one-
sentence bullet points, outlining where the experts agree (no
more than three points) and disagree (no more than three
points). The JCM editor will then upload the introduction,
both commentaries, and the summary in eJP.
Case Reports
While a full-length article or a Short-Form paper may contain
a case report section when the report is incidental to the rest of
the paper, a specific Case Report formatmust be usedwhen the
report constitutes the entire article.
A Case Report must include an abstract of no more than 50
words. The text starts with presentation of the case under the
section heading “Case Report”; there is no introductory text
before the Case Report heading. After the case is presented, the
rest of the text follows in a separate section after a ruled line to
separate the sections. No separate head is used for this short
discussion section, but paragraph lead-ins are permitted. The
total number of tables and figures (combined)must not exceed
3. For an example of a correctly formatted Case Report, see
J. Clin. Microbiol. 39:1678–1679, 2001.
Photo Quiz
A Photo Quiz submission should present the findings of some
relevant, interesting, and new observation pertinent to the
practice of clinical microbiology in which a photograph is par-
ticularly useful in conveying important information and
where the observation can serve as the basis for both a question
and an answer. The photographmay be of amicrograph, some
other laboratory material, a clinical lesion, or the results of an
imaging study.
A Photo Quiz consists of two parts: (i) a case presentation
featuring a photograph depicting some unusual and/or infor-
mative finding in clinical microbiology and (ii) an answer to
the quiz. The case presentation and the answer must be sub-
mitted as two separate articles. Note that authors and affilia-
tions are listed below the title.
Photo Quiz case presentation. The text in the Photo Quiz
case presentation should be limited to 200 to 300 words. The
header for the case presentation should read “Photo Quiz.”
Please include a photograph about 39 picas (6.5 inches)wide
and 28 picas (4.625 inches) high. Since photos appearing with
published Photo Quizzes appear on the cover of the journal, a
high-resolutionTIFF or EPS file is preferred. A short legend for
the photomust be provided, and the photomust be cited in the
case presentation. Refer to a recently published Photo Quiz for
correct formatting.
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Answer to Photo Quiz. The text of the answer to the Photo
Quiz should also be limited to 200 to 300 words. The header to
the answer should read “Answer to Photo Quiz.” Four to six
references may be cited at the end of the Photo Quiz answer.
Submission. The Photo Quiz case presentation should be
submitted in the “Photo Quiz” manuscript category. The
Photo Quiz answer should be submitted in the “Photo Quiz
Answer” manuscript category.
Letters to the Editor
Two types of Letters to the Editor may be submitted. The first
type (Comment Letter) is intended for comments on final,
typeset articles published in the journal (not on publish-
ahead-of-print manuscripts) and must cite published refer-
ences to support thewriter’s argument. The second type (New-
Data Letter) may report new, concise findings that are not
appropriate for publication as full-length papers or Short-
Form papers.
Letters may be no more than 500 words long and must be
typed double spaced. Refer to a recently published Letter for
correct formatting. Note that authors and affiliations are listed
below the title.
All Letters to the Editor must be submitted electronically,
and the type of Letter (New Data or Comment) must be se-
lected from the drop-down list in the submission form. For
Letters commenting on published articles, the cover letter
should state the volume and issue in which the article was
published, the title of the article, and the last name of the first
author. In the Abstract section of the submission form, put
“Not Applicable.” Letters to the Editor do not have abstracts.
Both types of Lettermust have a title, whichmust appear on the
manuscript and on the submission form. Figures and tables
should be kept to a minimum.
If the Letter is related to a published article, it will be sent to
the editor who handled the article in question. If the editor
believes that publication is warranted, he/she will solicit a reply
from the corresponding author of the article and give approval
for publication.
New-Data Letters will be assigned to an editor according to
subject matter and will be reviewed by that editor and/or a
reviewer.
Please note that some indexing/abstracting services do not
include Letters to the Editor in their databases.
Fast-Track Communications
The Fast-Track route is intended for accelerated review of
short communications that are of significant interest to clinical
microbiologists. Manuscripts are limited to 750 words, one
figure, one table, and 10 or fewer references. The format should
be the same as that of a New-Data Letter (see “Letters to the
Editor,” above). Fast-Track articles should be submitted via
the eJP online manuscript submission and peer review system.
A Fast-Track submission is subject to approval as such by
the editor in chief. If approved for the Fast-Track route, the
manuscript will be assigned to an appropriate JCM editor and
reviewed, according to the same standards applied for tradi-
tional manuscripts, within 1 week. If accepted, the manuscript
will be scheduled for the next available issue and edited. An
acceptance letter and copyright agreementwill bemailed to the
corresponding author. Proofs will be made available electron-
ically as for regular articles.
A Fast-Track submission that is not approved for the Fast-
Track route will be handled as a New-Data Letter according to
normal procedures.
Errata
The Erratum section provides ameans of correcting errors that
occurred during the writing, typing, editing, or publication
(e.g., a misspelling, a dropped word or line, or mislabeling in a
figure) of a published article. Submit Errata via the eJP online
manuscript submission and peer review system (see “Submis-
sion, Review, and Publication Processes”). In the Abstract sec-
tion of the submission form (a required field), put “Not Appli-
cable.” Upload the text of your Erratum as a Microsoft Word
file. Please see a recent issue for correct formatting.
Author Corrections
The Author Correction section provides a means of correcting
errors of omission (e.g., author names or citations) and errors
of a scientific nature that do not alter the overall basic results or
conclusions of a published article (e.g., an incorrect unit of
measurement or order of magnitude used throughout, con-
tamination of one of numerous cultures, or misidentification
of a mutant strain, causing erroneous data for only a [noncrit-
ical] portion of the study). Note that the addition of newdata is
not permitted.
For corrections of a scientific nature or issues involving au-
thorship, including contributions anduse or ownership of data
and/ormaterials, all disputing partiesmust agree, inwriting, to
publication of the Correction. For omission of an author’s
name, letters must be signed by the authors of the article and
the author whose name was omitted. The editor who handled
the article will be consulted if necessary.
Submit an Author Correction via the eJP online manuscript
submission and peer review system (see “Submission, Review,
and Publication Processes”). Select Author Correction as the
manuscript type. In the Abstract section of the submission
form (a required field), put “Not Applicable.” Upload the text
of your Author Correction as a Microsoft Word file. Please see
a recent issue for correct formatting. Signed letters of agree-
ment must be supplied as supplemental material for informa-
tion only (scanned PDF files).
Retractions
Retractions are reserved for major errors or breaches of ethics
that, for example, may call into question the source of the data
or the validity of the results and conclusions of an article. Sub-
mit Retractions via the eJP online manuscript submission and
peer review system (see “Submission, Review, and Publication
Processes”). In the Abstract section of the submission form (a
required field), put “Not Applicable.” Upload the text of your
Retraction as a Microsoft Word file. Letters of agreement
signed by all of the authors must be supplied as supplemental
material for information only (scanned PDF files). The Retrac-
tionwill be assigned to the editor in chief of the journal, and the
Instructions to Authors
14 January 2014, Instructions to Authors Journal of Clinical Microbiology jcm.asm.org
editor who handled the paper and the chairperson of the ASM
Journals Board will be consulted. If all parties agree to the
publication and content of the Retraction, it will be sent to the
Journals Department for publication.
ILLUSTRATIONS AND TABLES
Illustrations
Image manipulation. Digital images submitted for publica-
tion may be inspected by ASM production specialists for any
manipulations or electronic enhancements that may be con-
sidered to be the result of scientific misconduct based on the
guidelines provided below. Any images/data found to contain
manipulations of concernwill be referred to the editor in chief,
and authors may then be requested to provide their primary
data for comparison with the submitted image file. Investiga-
tion of the concerns may delay publication and may result in
revocation of acceptance and/or additional action by ASM.
Linear adjustments to contrast, brightness, and/or color are
generally acceptable, as long as the measures taken are neces-
sary to view elements that are already present in the data and
the adjustments are applied to the entire image and not just
specific areas. Unacceptable adjustments to images include,
but are not limited to, the removal or deletion, concealment,
duplication (copying and pasting), addition, selective en-
hancement, or repositioning of elements within the image.
Nonlinear adjustments made to images, such as changes to
gamma settings, should be fully disclosed in the figure legends
at the time of submission. In addition, images created by com-
piling multiple files, including noncontiguous portions of the
same image, should clearly distinguish that these multiple files
are not a single image. This can be done by “tooling,” or insert-
ing thin lines, between the individual images.
File types and formats. Illustrations may be continuous-
tone images, line drawings, or composites. Color graphics may
be submitted, but the cost of printing in colormust be borne by
the author. Suggestions about how to reduce costs and ensure
accurate color reproduction are given below.
On initial submission, figuresmay be uploaded as individual
PDF files or combined and uploaded as a single PDF file. Place
each legend in the text file, as well as on the same page with the
figure to assist review. At the modification stage, production-
quality digital filesmust be provided. The legends will be copy-
edited and typeset for final publication and should not be in-
cluded as part of the figure itself at this stage. All graphics
submitted with modified manuscripts must be bitmap, gray-
scale, or in the RGB (preferred) or CMYK color mode. See
“Color illustrations.” Halftone images (those with various
densities or shades) must be grayscale, not bitmap. JCM ac-
cepts TIFF or EPS files but discourages PowerPoint for either
black-and-white or color images.
For instructions on creating acceptable EPS and TIFF files,
refer to the Cadmus digital art website, http://art.cadmus.com
/da/index.jsp. PowerPoint requires users to pay close attention
to the fonts used in their images (see the section on fonts be-
low). If instructions for fonts are not followed exactly, images
prepared for publication are subject to missing characters, im-
properly converted characters, or shifting/obscuring of ele-
ments or text in the figure. For proper font use in PowerPoint
images, refer to the Cadmus digital art website, http://art
.cadmus.com/da/instructions/ppt_disclaimer.jsp. Note that,
due to page composition system requirements, youmust verify
that your PowerPoint files can be converted to PDF without
any errors.
We strongly recommend that before returning theirmod-
ified manuscripts, authors check the acceptability of their
digital images for production by running their files through
Rapid Inspector, a tool provided at the following URL: http:
//rapidinspector.cadmus.com/RapidInspector/zmw/index.jsp.
Rapid Inspector is an easy-to-use,Web-based application that iden-
tifies file characteristics thatmay render the image unusable for pro-
duction.
If you have additional questions about using the Rapid In-
spector preflighting tool, please send an e-mail inquiry to
helpdesk.digitalartsupport@cenveo.com.
Minimumresolution. It is extremely important that a high
enough resolution is used. All separate images that you import
into a figure file must be at the correct resolution before they
are placed. (For instance, placing a 72-dpi image in a 300-dpi
EPS file will not result in the placed image meeting the mini-
mumrequirements for file resolution.)Note, however, that the
higher the resolution, the larger the file and the longer the
upload time. Publication quality will not be improved by using
a resolution higher than the minimum. Minimum resolutions
are as follows:
• 300 dpi for grayscale and color
• 600 dpi for combination art (lettering and images)
• 1,200 dpi for line art
Size. All graphics should be submitted at their intended
publication size; that is, the image uploaded should be 100%
of its print dimensions so that no reduction or enlargement is
necessary. Resolution must be at the required level at the sub-
mitted size. Include only the significant portion of an illustra-
tion. White space must be cropped from the image, and excess
space between panel labels and the image must be eliminated.
• Maximum width for a 1-column figure: 20.6 picas (ca.
8.7 cm)
• Maximum width for a 2-column figure: 42 picas (ca.
17.8 cm)
• Minimumwidth for a 2-column figure: 26 picas (11.1 cm)
• Maximum height for a standard figure: 54.7 picas (ca.
23.2 cm)
• Maximum height for an oversized figure (no running
title); 57.4 picas (ca. 24.3 cm)
Contrast. Illustrations must contain sufficient contrast to
be viewed easily on a monitor or on the printed page.
Labeling and assembly. All final lettering and labelingmust
be incorporated into the figures. On initial submission, illus-
trations should be provided as PDFfiles, with the legends in the
text file and with a legend beneath each image to assist review.
At the modification stage, production-quality digital figure
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files (without legends) must be provided. Put the figure num-
ber well outside the boundaries of the image itself. (Number-
ing may need to be changed at the copyediting stage.) Each
figure must be uploaded as a separate file, and any multipanel
figures must be assembled into one file; i.e., rather than up-
loading a separate file for each panel in a figure, assemble all
panels in one piece and supply them as one file.
Fonts. To avoid font problems, set all type in one of the
following fonts: Arial, Helvetica, Times Roman, European PI,
Mathematical PI, or Symbol. Courier may be used but should
be limited to nucleotide or amino acid sequences, where a non-
proportional (monospace) font is required. All fonts other
than these must be converted to paths (or outlines) in the ap-
plication with which they were created. For proper font use in
PowerPoint images, refer to the Cadmus digital art website,
http://art.cadmus.com/da/instructions/ppt_disclaimer.jsp.
Color illustrations. Color costs must be borne by the au-
thor. See “Publication Fees.” All figures submitted in color
will be processed as color. Adherence to the following guide-
lines will help tominimize costs and to ensure color reproduc-
tion that is as accurate as possible.
The final online version is considered the version of record
for JCM and all other ASM journals. To maximize online re-
production, color illustrations should be supplied in the RGB
color mode as either (i) RGB TIFF images with a resolution of
at least 300 pixels per inch (raster files, consisting of pixels) or
(ii) Illustrator-compatible EPS files with RGB color elements
(vector files, consisting of lines, fonts, fills, and images). CMYK
files are also accepted. Other than in color space, CMYK files
must meet the same production criteria as RGB files. The RGB
color space is the native color space of computer monitors and
of most of the equipment and software used to capture scien-
tific data, and it can display a wider range of colors (especially
bright fluorescent hues) than the CMYK (cyan, magenta, yel-
low, black) color space used by print devices that put ink (or
toner) on paper. For the print version (and reprints), ASM’s
print provider will automatically create CMYK versions of
color illustrations from the supplied RGB versions. Color in
the print journal may not match that in the online journal of
record because of the smaller range of colors capable of being
reproduced by CMYK inks on a printing press. For additional
information on RGB versus CMYK color, refer to the Cadmus
digital art site, http://art.cadmus.com/da/guidelines_rgb.jsp.
Drawings
Submit graphs, charts, complicated chemical or mathematical
formulas, diagrams, and other drawings as finished products
not requiring additional artwork or typesetting. All elements,
including letters, numbers, and symbols, must be easily read-
able, and both axes of a graph must be labeled. Keep in mind
that the journal is published both in print and online and that
the same electronic files submitted by the authors are used to
produce both.
When creating line art, please use the following guidelines:
(i) All art must be submitted at its intended publication
size. For acceptable dimensions, see “Size,” above.
(ii) Avoid using screens (i.e., shading) in line art. It can be
difficult and time-consuming to reproduce these images with-
out moire´ patterns. Various pattern backgrounds are prefera-
ble to screens as long as the patterns are not imported from
another application. If you must use images containing
screens,
(a) Generate the image at line screens of 85 lines per inch
or less.
(b) When applying multiple shades of gray, differentiate
the gray levels by at least 20%.
(c) Never use levels of gray below 5% or above 95%, as
they are likely to fade out or become totally black when
output.
(iii) Use thick, solid lines that are no finer than 1 point in
thickness.
(iv) No type should be smaller than 6 points at the final
publication size.
(v) Avoid layering type directly over shaded or textured
areas.
(vi) Avoid the use of reversed type (white lettering on a black
background).
(vii) Avoid heavy letters, which tend to close up, and un-
usual symbols, which the printer may not be able to reproduce
in the legend.
(viii) If colors are used, avoid using similar shades of the
same color and avoid very light colors.
In figure ordinate and abscissa scales (aswell as table column
headings), avoid the ambiguous use of numbers with expo-
nents. Usually, it is preferable to use the appropriate Syste`me
International d’Unite´s (SI) symbols ( for 106, m for 103, k
for 103, and M for 106, etc.). Thus, a representation of 20,000
cpm on a figure ordinate should be made by the number 20
accompanied by the label kcpm. A complete listing of SI sym-
bols can be found in the International Union of Pure and Ap-
plied Chemistry (IUPAC) publication Quantities, Units and
Symbols in Physical Chemistry, 3rd ed. (RSC Publishing, Cam-
bridge, United Kingdom, 2011); an abbreviated list is available
at http://old.iupac.org/reports/1993/homann/index.html.
When powers of 10 must be used, the journal requires that
the exponent power be associated with the number shown. In
representing 20,000 cells per ml, the numeral of the ordinate
should be “2” and the label should be “104 cells per ml” (not
“cells per ml  104”). Likewise, an enzyme activity of 0.06
U/ml might be shown as 6 accompanied by the label 102
U/ml. The preferred designation is 60 mU/ml (milliunits per
milliliter).
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Presentation of Nucleic Acid Sequences
Long nucleic acid sequencesmust be presented as figures in the
following format to conserve space. Print the sequence in lines
of approximately 100 to 120 nucleotides in a nonproportional
(monospace) font that is easily legible when published with a
line length of 6 inches (ca. 15.2 cm). If possible, lines of nucleic
acid sequence should be further subdivided into blocks of 10 or
20 nucleotides by spaces within the sequence or by marks
above it. Uppercase and lowercase letters may be used to des-
ignate the exon-intron structure or transcribed regions, etc., if
the lowercase letters remain legible at a 6-inch (ca. 15.2-cm)
line length. Number the sequence line by line; place numerals
representing the first base of each line to the left of the lines.
Minimize spacing between lines of sequence, leaving room
only for annotation of the sequence. Annotation may include
boldface, underlining, brackets, and boxes, etc. Encoded
amino acid sequences may be presented, if necessary, immedi-
ately above or below the first nucleotide of each codon, by
using the single-letter amino acid symbols. Comparisons of
multiple nucleic acid sequences should conform as nearly as
possible to the same format.
Figure Legends
On initial submission, each legend should be placed in the text
file and be incorporated into the image file beneath the figure
to assist review.
Legends should provide enough information so that the fig-
ure is understandable without frequent reference to the text.
However, detailed experimental methodsmust be described in
the Materials and Methods section, not in a figure legend. A
method that is unique to one of several experiments may be
reported in a legend only if the discussion is very brief (one or
two sentences). Define all symbols used in the figure and define
all abbreviations that are not used in the text.
Tables
Tables that contain artwork, chemical structures, or shading
must be submitted as illustrations in an acceptable format at
the modification stage. The preferred format for regular tables
is Microsoft Word; however, WordPerfect and Acrobat PDF
are also acceptable. Note that a straight Excel file is not cur-
rently an acceptable format. Excel files must be either embed-
ded in aWord orWordPerfect document or converted to PDF
before being uploaded.
Tables should be formatted as follows. Arrange the data so
that columns of like material read down, not across. The
headings should be sufficiently clear so that themeaning of the
data is understandable without reference to the text. See the
“Abbreviations” section of these Instructions for those that
should be used in tables. Explanatory footnotes are acceptable,
but more-extensive table “legends” are not. Footnotes should
not include detailed descriptions of the experiment. Tables
must include enough information to warrant table format;
those with fewer than six pieces of data will be incorporated
into the text by the copy editor. Table 1 is an example of a
well-constructed table.
NOMENCLATURE
Chemical and Biochemical Nomenclature
The recognized authority for the names of chemical com-
pounds is Chemical Abstracts (CAS; http://www.cas.org/) and
its indexes.TheMerck Index, 15th ed. (RSCBooks, Cambridge,
UK, 2013), is also an excellent source. For biochemical termi-
nology, including abbreviations and symbols, consult Biochemi-
cal Nomenclature andRelatedDocuments (Portland Press, Lon-
don, United Kingdom, 1992) available at http://www.chem
.qmul.ac.uk/iupac/bibliog/white.html, and the instructions to
authors of the Journal of Biological Chemistry and the Archives
of Biochemistry and Biophysics.
Do not express molecular weight in daltons; molecular
weight is a unitless ratio. Molecular mass is expressed in dal-
tons.
For enzymes, use the recommended (trivial) name assigned
by theNomenclatureCommittee of the InternationalUnion of
Biochemistry (IUB) as described in EnzymeNomenclature (Ac-
ademic Press, Inc., New York, NY, 1992) and its supplements
and at http://www.chem.qmul.ac.uk/iubmb/enzyme/. If a
nonrecommended name is used, place the proper (trivial)
name in parentheses at first use in the abstract and text. Use
the EC number when one has been assigned. Authors of pa-
pers describing enzymological studies should review the stan-
dardsof theSTRENDACommission for informationrequired for
adequate description of experimental conditions and for report-
ing enzyme activity data (http://www.beilstein-institut.de/en
/projekte/strenda/guidelines/).
For nomenclature of restriction enzymes, DNA methyl-
transferases, homing endonucleases, and their genes, refer to
the article by Roberts et al. (Nucleic Acids Res. 31:1805–1812,
2003).
Drugs
Whenever possible, use generic names of drugs; the use of trade
names is not permitted.
Nomenclature of Microorganisms
Binary names, consisting of a generic name and a specific epi-
thet (e.g., Escherichia coli), must be used for all microorgan-
isms. Names of categories at or above the genus level may be
used alone, but specific and subspecific epithets may not. A
TABLE 1 Distribution of protein and ATPase in fractions of dialyzed
membranesa
Membrane Fraction
ATPase
U/mg of protein Total U
Control Depleted membrane 0.036 2.3
Concentrated supernatant 0.134 4.82
E1 treated Depleted membrane 0.034 1.98
Concentrated supernatant 0.11 4.6
a Specific activities of ATPase of nondepleted membranes from control and treated
bacteria were 0.21 and 0.20, respectively.
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specific epithet must be preceded by a generic name, written
out in full the first time it is used in a paper. Thereafter, the
generic name should be abbreviated to the initial capital letter
(e.g., E. coli), provided there can be no confusion with other
genera used in the paper. Names of all taxa (kingdoms, phyla,
classes, orders, families, genera, species, and subspecies) are
printed in italics and should be italicized in the manuscript;
strain designations and numbers are not. Vernacular (com-
mon) names should be in lowercase roman type (e.g., strepto-
coccus, brucella). For Salmonella, genus, species, and subspe-
cies names should be rendered in standard form: Salmonella
enterica at first use, S. enterica thereafter; Salmonella enterica
subsp. arizonae at first use, S. enterica subsp. arizonae thereaf-
ter. Names of serovars should be in roman type with the first
letter capitalized: Salmonella enterica serovar Typhimurium.
After the first use, the serovar may also be given without a
species name: Salmonella Typhimurium, S. Typhimurium, or
Salmonella serovar Typhimurium. For other information re-
garding serovar designations, seeAntigenic Formulae of the Sal-
monella Serovars, 9th ed. (P. A. D. Grimont and F.-X. Weill,
WHO Collaborating Centre for Reference and Research on
Salmonella, Institut Pasteur, Paris, France, 2007; see http:
//www.pasteur.fr/ip/portal/action/WebdriveActionEvent/oid/
01s-000036-089). For a summary of the current standards for
Salmonella nomenclature and the Kaufmann-White criteria,
see the article by Brenner et al. (J. Clin. Microbiol. 38:2465–
2467, 2000), the opinion of the Judicial Commission of the
International Committee on Systematics of Prokaryotes (Int. J.
Syst. Evol. Microbiol. 55:519–520, 2005), and the article by
Tindall et al. (Int. J. Syst. Evol. Microbiol. 55:521–524, 2005).
The spelling of bacterial names should follow the Approved
Lists of Bacterial Names (Amended) & Index of the Bacterial and
Yeast Nomenclatural Changes (V. B. D. Skerman et al., ed.,
American Society forMicrobiology,Washington, DC, 1989) and
the validation lists and notification lists published in the
International Journal of Systematic and Evolutionary Micro-
biology (formerly the International Journal of Systematic Bacte-
riology) since January 1989. In addition, two sites on the World
WideWeb list currentapprovedbacterialnames:ProkaryoticNo-
menclature Up-to-Date (http://www.dsmz.de/bacterial-diversity
/prokaryotic-nomenclature-up-to-date.html) and List of Pro-
karyotic Names with Standing in Nomenclature (http://www
.bacterio.net/). If there is reason to use a name that does not
have standing in nomenclature, the name should be enclosed
in quotationmarks in the title and at its first use in the abstract
and the text and an appropriate statement concerning the no-
menclatural status of the name should be made in the text.
“Candidatus” species should always be set in quotation marks.
For guidelines regarding newnames and descriptions of new
genera and species, see the articles by Tindall (Int. J. Syst. Bac-
teriol. 49:1309–1312, 1999) and Stackebrandt et al. (Int. J. Syst.
Evol. Microbiol. 52:1043–1047, 2002). To validate new names
and/or combinations, authors must submit three copies of
their published article to the International Journal of Systematic
and Evolutionary Microbiology.
It is recommended that a strain be deposited in at least two
recognized culture collections in different countries when that
strain is necessary for the description of a new taxon (Int. J.
Syst. Evol. Microbiol. 50:2239–2244, 2000).
Since the classification of fungi is not complete, it is the
responsibility of the author to determine the accepted bino-
mial for a given organism. Sources for these names include
The Yeasts: a Taxonomic Study, 5th ed. (C. P. Kurtzman, J. W.
Fell, and T. Boekhout, ed., Elsevier Science, Amsterdam,
Netherlands, 2011), and Dictionary of the Fungi, 10th ed.
(P.M. Kirk, P. F. Cannon, D.W.Minter, and J. A. Stalpers, ed.,
CABI International, Wallingford, Oxfordshire, United King-
dom, 2008); see also http://www.speciesfungorum.org/Names
/Fundic.asp.
Names used for viruses should be those approved by the
International Committee on Taxonomy of Viruses (ICTV)
and reported on the ICTV Virus Taxonomy website (http:
//www.ictvonline.org/index.asp). In addition, the recommen-
dations of the ICTV regarding the use of species names should
generally be followed: when the entire species is discussed as a
taxonomic entity, the species name, as with other taxa, is italic
and has the first letter and any proper nouns capitalized (e.g.,
Tobacco mosaic virus, Murray Valley encephalitis virus). When
the behavior or manipulation of individual viruses is dis-
cussed, the vernacular (e.g., tobaccomosaic virus,Murray Val-
ley encephalitis virus) should be used. If desired, synonyms
may be added parenthetically when the name is first men-
tioned. Approved generic (or group) and family names may
also be used.
Microorganisms, viruses, and plasmids should be given des-
ignations consisting of letters and serial numbers. It is gener-
ally advisable to include aworker’s initials or a descriptive sym-
bol of locale or laboratory, etc., in the designation. Each new
strain, mutant, isolate, or derivative should be given a new
(serial) designation. This designation should be distinct from
those of the genotype and phenotype, and italicized genotypic
and phenotypic symbols should not be included. Plasmids are
named with a lowercase “p” followed by the designation in
uppercase letters and numbers. To avoid the use of the same
designation as that of awidely used strain or plasmid, check the
designation against a publication database such as Medline.
Genetic Nomenclature
To facilitate accurate communication, it is important that stan-
dard genetic nomenclature beusedwhenever possible and that
deviationsorproposals fornewnaming systemsbe endorsed
by an appropriate authoritative body. Review and/or publi-
cation of submittedmanuscripts that contain new or nonstan-
dard nomenclature may be delayed by the editor or the Jour-
nals Department so that they may be reviewed.
Bacteria. The genetic properties of bacteria are described in
terms of phenotypes and genotypes. The phenotype describes
the observable properties of an organism. The genotype refers
to the genetic constitution of an organism, usually in reference
to some standard wild type. Use the recommendations of De-
merec et al. (Genetics 54:61–64, 1966) as a guide to the use of
these terms. If your manuscript contains information includ-
ing genetic nomenclature, please refer to the Instructions to
Authors of the Journal of Bacteriology.
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“Mutant” versus “mutation.” Keep in mind the distinc-
tion between a mutation (an alteration of the primary se-
quence of the genetic material) and amutant (a strain carrying
one ormoremutations). Onemay speak about themapping of
a mutation, but one cannot map a mutant. Likewise, a mutant
has no genetic locus, only a phenotype.
“Homology” versus “similarity.” For use of terms that de-
scribe relationships between genes, consult the articles by
Theissen (Nature 415:741, 2002) and Fitch (Trends Genet. 16:
227–231, 2000). “Homology” implies a relationship between
genes that have a common evolutionary origin; partial homol-
ogy is not recognized. When sequence comparisons are dis-
cussed, it is more appropriate to use the term “percent se-
quence similarity” or “percent sequence identity,” as
appropriate.
Tetracycline resistance determinants. The nomenclature
for tetracycline resistance determinants is based on the pro-
posal of Levy et al. (Antimicrob. Agents Chemother. 43:1523–
1524, 1999). The style for such determinants is, e.g., Tet B; the
space helps distinguish the determinant designation from that
for phenotypes and proteins (TetB). The above-referenced ar-
ticle also gives the correct format for genes, proteins, and de-
terminants in this family.
Locus tags. Locus tags are systematic, unique identifiers
that are assigned to each gene in GenBank. All genes men-
tioned in a manuscript should be traceable to their sequences
by the reader, and locus tags may be used for this purpose in
manuscripts to identify uncharacterized genes. In addition,
authors should check GenBank to make sure that they are us-
ing the correct, up-to-date format for locus tags (e.g., upper-
case versus lowercase letters and the presence or absence of an
underscore, etc.). Locus tag formats vary between different or-
ganisms and also may be updated for a given organism, so it is
important to check GenBank at the time of manuscript prep-
aration.
Viruses. The genetic nomenclature for viruses differs from
that for bacteria. Inmost instances, viruses have no phenotype,
since they have no metabolism outside host cells. Therefore,
distinctions betweenphenotype and genotype cannot bemade.
Superscripts are used to indicate hybrid genomes. Genetic
symbols may be one, two, or three letters.
Eukaryotes. FlyBase (http://flybase.org/) is the genetic no-
menclature authority for Drosophila melanogaster. WormBase
(http://wormbase.org/#01-23-6) is the genetic nomenclature
authority for Caenorhabditis elegans. When naming genes for
Aspergillus species, the nomenclature guidelines posted at
http://www.aspergillus.org.uk/indexhome.htm?secure/seq
uence_info/nomenclature.htm should be followed, and the
Aspergillus Genome Database (http://www.aspgd.org/) should
be searched to ensure that any new name is not already in
use. The Saccharomyces Genome Database (http://www
.yeastgenome.org/) and the Candida Genome Database http:
//www.candidagenome.org/) are authorities for Saccharomyces
cerevisiae and Candida albicans genetic nomenclature, respec-
tively. For more information about the genetic nomenclature
of eukaryotes, see the Instructions to Authors for Eukaryotic
Cell and Molecular and Cellular Biology.
ABBREVIATIONS AND CONVENTIONS
Verb Tense
ASM strongly recommends that for clarity you use the past tense
to narrate particular events in the past, including the procedures,
observations, and data of the study that you are reporting. Use
the present tense for your own general conclusions, the con-
clusions of previous researchers, and generally accepted facts.
Thus,most of the abstract,Materials andMethods, andResults
will be in the past tense, andmost of the introduction and some
of the Discussion will be in the present tense.
Be aware that it may be necessary to vary the tense in a single
sentence. For example, it is correct to say “White (30) demon-
strated that XYZ cells grow at pH 6.8,” “Figure 2 shows that
ABC cells failed to grow at room temperature,” and “Air was
removed from the chamber and the mice died, which proves
thatmice require air.” In reporting statistics and calculations, it
is correct to say “The values for the ABC cells are statistically
significant, indicating that the drug inhibited . . .”
For an in-depth discussion of tense in scientific writing, see
How ToWrite and Publish a Scientific Paper, 7th ed.
Abbreviations
General. Abbreviations should be used as an aid to the reader,
rather than as a convenience for the author, and therefore their
use should be limited.Abbreviations other than those recom-
mended by the IUPAC-IUB (Biochemical Nomenclature and
Related Documents, 1992) should be used only when a case can
be made for necessity, such as in tables and figures.
It is often possible to use pronouns or to paraphrase a long
word after its first use (e.g., “the drug” or “the substrate”).
Standard chemical symbols and trivial names or their symbols
(folate, Ala, and Leu, etc.) may also be used.
Define each abbreviation and introduce it in parentheses the
first time it is used; e.g., “Cultureswere grown inEagleminimal
essential medium (MEM).” Generally, eliminate abbreviations
that are not used at least three times in the text (including
tables and figure legends).
Not requiring introduction. In addition to abbrevia-
tions for Syste`me International d’Unite´s (SI) units of mea-
surement, other common units (e.g., bp, kb, and Da), and
chemical symbols for the elements, the following should be
used without definition in the title, abstract, text, figure leg-
ends, and tables:
DNA (deoxyribonucleic acid)
cDNA (complementary DNA)
RNA (ribonucleic acid)
cRNA (complementary RNA)
RNase (ribonuclease)
DNase (deoxyribonuclease)
rRNA (ribosomal RNA)
mRNA (messenger RNA)
tRNA (transfer RNA)
AMP, ADP, ATP, dAMP,
ddATP, and GTP, etc. (for the
respective 5 phosphates
of adenosine and other
nucleosides) (add 2-,
3-, or 5- when needed for
contrast)
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ATPase and dGTPase, etc.
(adenosine triphosphatase
and deoxyguanosine
triphosphatase, etc.)
NAD (nicotinamide adenine
dinucleotide)
NAD (nicotinamide adenine
dinucleotide, oxidized)
NADH (nicotinamide adenine
dinucleotide, reduced)
NADP (nicotinamide adenine
dinucleotide phosphate)
NADPH (nicotinamide adenine
dinucleotide phosphate,
reduced)
NADP (nicotinamide adenine
dinucleotide phosphate,
oxidized)
poly(A) and poly(dT), etc.
(polyadenylic acid and
polydeoxythymidylic acid,
etc.)
oligo(dT), etc. (oligodeoxy-
thymidylic acid, etc.)
UV (ultraviolet)
PFU (plaque-forming units)
CFU (colony-forming units)
MIC (minimal inhibitory
concentration)
Tris (tris[hydroxymethyl]
aminomethane)
DEAE (diethylaminoethyl)
EDTA (ethylenediamine-
tetraacetic acid)
EGTA (ethylene glycol-bis[-
aminoethyl ether]-N,N,N,N-
tetraacetic acid)
HEPES (N-2-hydroxyethyl-
piperazine-N-2-
ethanesulfonic acid)
PCR (polymerase chain reaction)
AIDS (acquired immuno-
deficiency syndrome)
Abbreviations for cell lines (e.g., HeLa) also need not be de-
fined.
The following abbreviations should be used without defini-
tion in tables:
amt (amount)
approx (approximately)
avg (average)
concn (concentration)
diam (diameter)
expt (experiment)
exptl (experimental)
ht (height)
mo (month)
mol wt (molecular weight)
no. (number)
prepn (preparation)
SD (standard deviation)
SE (standard error)
SEM (standard error of the
mean)
sp act (specific activity)
sp gr (specific gravity)
temp (temperature)
tr (trace)
vol (volume)
vs (versus)
wk (week)
wt (weight)
yr (year)
Drugs. Should an author decide to abbreviate the names of
antimicrobial agents in a manuscript, the following standard
abbreviations are strongly recommended.
Antibacterial agents. Use the indicated abbreviations for
the following antibacterial agents.
amikacin (AMK)
amoxicillin (AMX)
amoxicillin-clavulanic acid (AMC)
ampicillin (AMP)
ampicillin-sulbactam (SAM)
azithromycin (AZM)
azlocillin (AZL)
aztreonam (ATM)
carbenicillin (CAR)
cefaclor (CEC)
cefadroxil (CFR)
cefamandole (FAM)
cefazolin (CFZ)
cefdinir (CDR)
cefditoren (CDN)
cefepime (FEP)
cefetamet (FET)
cefixime (CFM)
cefmetazole (CMZ)
cefonicid (CID)
cefoperazone (CFP)
cefotaxime (CTX)
cefotetan (CTT)
cefoxitin (FOX)
cefpodoxime (CPD)
cefprozil (CPR)
ceftazidime (CAZ)
ceftibuten (CTB)
ceftizoxime (ZOX)
ceftriaxone (CRO)
cefuroxime (axetil) and
cefuroxime (sodium) (CXM)
cephalexin (LEX)
cephalothin (CEF)
cephapirin (HAP)
cephradine (RAD)
chloramphenicol (CHL)
cinoxacin (CIN)
ciprofloxacin (CIP)
clarithromycin (CLR)
clinafloxacin (CLX)
clindamycin (CLI)
daptomycin (DAP)
dicloxacillin (DCX)
dirithromycin (DTM)
doxycycline (DOX)
enoxacin (ENX)
erythromycin (ERY)
fleroxacin (FLE)
fosfomycin (FOF)
gatifloxacin (GAT)
gentamicin (GEN)
grepafloxacin (GRX)
imipenem (IPM)
kanamycin (KAN)
levofloxacin (LVX)
linezolid (LZD)
lomefloxacin (LOM)
loracarbef (LOR)
meropenem (MEM)
methicillin (MET)
mezlocillin (MEZ)
minocycline (MIN)
moxalactam (MOX)
moxifloxacin (MXF)
nafcillin (NAF)
nalidixic acid (NAL)
netilmicin (NET)
nitrofurantoin (NIT)
norfloxacin (NOR)
ofloxacin (OFX)
oxacillin (OXA)
penicillin (PEN)
piperacillin (PIP)
piperacillin-tazobactam (TZP)
quinupristin-dalfopristin
(Synercid) (Q-D)
rifabutin (RFB)
rifampin (RIF)
rifapentine (RFP)
sparfloxacin (SPX)
spectinomycin (SPT)
streptomycin (STR)
teicoplanin (TEC)
telithromycin (TEL)
tetracycline (TET)
ticarcillin (TIC)
ticarcillin-clavulanic acid (TIM)
tobramycin (TOB)
trimethoprim (TMP)
trimethoprim-sulfamethoxazole
(SXT)
trovafloxacin (TVA)
vancomycin (VAN)
-Lactamase inhibitors. Use the indicated abbreviations
for the following -lactamase inhibitors.
clavulanic acid (CLA)
sulbactam (SUL)
tazobactam (TZB)
Antifungal agents. Use the indicated abbreviations for the
following antifungal agents.
amphotericin B (AMB)
clotrimazole (CLT)
flucytosine (5FC)
fluconazole (FLC)
itraconazole (ITC)
ketoconazole (KTC)
nystatin (NYT)
terbinafine (TRB)
voriconazole (VRC)
Antiviral agents. Use the indicated abbreviations for the
following antiviral agents.
acyclovir (ACV)
cidofovir (CDV)
famciclovir (FCV)
foscarnet (FOS)
ganciclovir (GCV)
penciclovir (PCV)
valacyclovir (VCV)
zidovudine (AZT)
Reporting Numerical Data
Standard metric units are used for reporting length, weight, and
volume. For these units and formolarity, use the prefixesm,, n,
and p for 103, 106, 109, and 1012, respectively. Likewise,
use the prefix k for 103. Avoid compound prefixes such as m
or . Use g/ml or g/g in place of the ambiguous ppm.
Units of temperature are presented as follows: 37°C or 324 K.
When fractions are used to express units such as enzymatic
activities, it is preferable to use whole units, such as “g” or
“min,” in the denominator instead of fractional or multiple
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units, such as g or 10 min. For example, “pmol/min” is pref-
erable to “nmol/10min,” and “mol/g” is preferable to “nmol/
g.” It is also preferable that an unambiguous form, such as
exponential notation, be used; for example, “mol g1min1”
is preferable to “mol/g/min.” Always report numerical data
in the appropriate SI units.
Representation of data as accurate to more than two signif-
icant figures must be justified by presentation of appropriate
statistical analyses.
For a review of some common errors associatedwith statistical
analyses and reports, plus guidelines on how to avoid them, see
the article by Olsen (Infect. Immun. 71:6689–6692, 2003).
For a review of basic statistical considerations for virology
experiments, see the article by Richardson and Overbaugh
(J. Virol. 79:669–676, 2005).
Statistics
Statistical analysis of data is a crucial component of scientific
publication. Authors who are unsure of proper statistical anal-
ysis should have their manuscripts checked by a qualified stat-
istician.
The following is a list of important items that must be con-
sidered before manuscript submission. Deficiencies in any of
these areas may delay review and/or publication.
(i) Statistical analyses were performed on all quantitative
data regardless of how significant the differences look in the
tables or figures.
(ii) Data were appropriately analyzed as parametric (nor-
mally distributed) or nonparametric data.
(iii) Parametric and nonparametric data are presented ap-
propriately. Means and standard deviations or standard errors
are appropriate means of presenting data analyzed by para-
metric analyses (i.e., t test and analysis of variance [ANOVA]),
but only medians and surrounding levels (quartiles, quin-
tiles, and 10th and 90th percentiles, etc.) are appropriate for
nonparametric statistics (Mann-Whitney test and Kruskal-
Wallis test, etc.). Means have no meaning in nonparametric
analyses.
(iv) For any data in which there are more than two compar-
isons (i.e., between one control andmore than one experimen-
tal group), an analysis must be done for multigroup compari-
sons. Such an analysis would usually be an ANOVA for
parametric data or a Kruskal-Wallis test for nonparametric
data. t tests cannot be used when more than two groups are
being compared (except as indicated below). Failure to use
multigroup tests generates type 1 errors: concluding that two
data sets within the overall data set being compared are differ-
ent when in fact they are not. Exception: some statisticians
argue that two-group comparisons can be used onmultigroup
data if the expected outcomes are appropriately anticipated
before the experiment. For example, data generated by individ-
ually testing two unrelated factors for their effects on a target
with only a single, untreated target as a control could be ap-
propriately analyzed by t tests instead of ANOVA.
(v) For all appropriate multigroup comparisons, two P val-
ues must be generated and provided in the manuscript. The
main P value applies to the overall data set and indicates that
within that data set at least two groups differ from each other.
The overall P value does not indicate which two groups are
different. The main P value and the overall P value should be
computed by using a post hoc test. For ANOVA, these post hoc
tests are usually Dunnett’s test (used to compare multiple ex-
perimental groups to a single control), the Fisher protected
least significant difference (PLSD) test, the Tukey-Kramer test,
and the Games-Howell test. Others may be used. Note that
each post hoc test has certain underlying assumptions that may
not be applicable to the data under analysis. For a Kruskal-
Wallis nonparametric ANOVA, the Dunn procedure is appro-
priate to generate P values for two-group comparisons.
(vi) Data presented as endpoints (i.e., LD50 and ID50, etc.)
contain both the calculated value and a confidence interval
with a statistical significance associated with it (95%, 99%, or
similar confidence interval), calculated by logit or probit anal-
ysis. Simple LD50 values, such as Reed-Muench calculations,
may not be used alone.
(vii) When samples are taken multiple times from one ex-
perimental entity (i.e., multiple serum samples from one ani-
mal, gross pathology scoresmeasured for the same animal over
time or growth curves, etc.), one cannot use analyses such as t
tests, ANOVA, or the Mann-Whitney test, etc., because these
tests assume that each measure is independent. An entity with
a high score on day 1 is more likely to have a high score on day
2 than is an entity with a low score. It is likely that some expert
statistical help will be needed for these situations, usually in-
volving regression analysis or survival analysis, etc.
(viii) Statistical significance and biological significance are
not the same. There is nothing magical about a P value of 0.05.
When results from large sample sizes are compared, a P value
of0.05 will often be obtained, as P value is a function of both
sample size and effect size. If sample sizes are large, thenmore-
rigorous (i.e., smaller) P values may be desirable. If sample
sizes are small, P values of	0.05 may still be important. There
should be both statistical and biological significance to the re-
sults and conclusions in the manuscript.
For a review of some common errors associated with statis-
tical analyses and reports, plus guidelines on how to avoid them,
see the article by Olsen (Infect. Immun. 71:6689–6692, 2003).
For a review of basic statistical considerations for virology
experiments, see the article by Richardson and Overbaugh
(J. Virol. 79:669–676, 2005).
Isotopically Labeled Compounds
For simplemolecules, labeling is indicated in the chemical for-
mula (e.g., 14CO2,
3H2O, and H2
35SO4). Brackets are not used
when the isotopic symbol is attached to the name of a com-
pound that in its natural state does not contain the element
(e.g., 32S-ATP) or to aword that is not a specific chemical name
(e.g., 131I-labeled protein, 14C-amino acids, and 3H-ligands).
For specific chemicals, the symbol for the isotope intro-
duced is placed in square brackets directly preceding the part of
the name that describes the labeled entity. Note that configu-
ration symbols andmodifiers precede the isotopic symbol. The
following examples illustrate correct usage:
[14C]urea
L-[methyl-14C]methionine
[2,3-3H]serine
[
-14C]lysine
UDP-[U-14C]glucose
E. coli [32P]DNA
fructose 1,6-[1-32P]bisphosphate
[-32P]ATP
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